<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">eClinicalMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EClinicalMedicine</journal-id><journal-id journal-id-type="pmc-domain-id">3674</journal-id><journal-id journal-id-type="pmc-domain">eclinm</journal-id><journal-title-group><journal-title>eClinicalMedicine</journal-title></journal-title-group><issn pub-type="epub">2589-5370</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12766425</article-id><article-id pub-id-type="pmcid-ver">PMC12766425.1</article-id><article-id pub-id-type="pmcaid">12766425</article-id><article-id pub-id-type="pmcaiid">12766425</article-id><article-id pub-id-type="pmid">41497507</article-id><article-id pub-id-type="doi">10.1016/j.eclinm.2025.103618</article-id><article-id pub-id-type="pii">S2589-5370(25)00552-8</article-id><article-id pub-id-type="publisher-id">103618</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Incidence of non-colorectal/endometrial malignancies in individuals with Lynch syndrome: a retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Negro</surname><given-names initials="S">Silvia</given-names></name><email>silvia.negro@unipd.it</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref><xref rid="fn1" ref-type="fn">n</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Celotto</surname><given-names initials="F">Francesco</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">n</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Schiavi</surname><given-names initials="F">Francesca</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Scarpa</surname><given-names initials="M">Marco</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Mammi</surname><given-names initials="I">Isabella</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Rossi</surname><given-names initials="S">Silvia</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Dell&#8217;Atti</surname><given-names initials="L">Lorenzo</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>De Grandis</surname><given-names initials="MC">Maria Caterina</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Crivellari</surname><given-names initials="G">Gino</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Fassan</surname><given-names initials="M">Matteo</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Agostini</surname><given-names initials="M">Marco</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Spolverato</surname><given-names initials="G">Gaya</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Cappello</surname><given-names initials="F">Filippo</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>D'Angelo</surname><given-names initials="E">Edoardo</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Milella</surname><given-names initials="M">Michele</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Bencivenga</surname><given-names initials="M">Maria</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Pilati</surname><given-names initials="P">Pierluigi</given-names></name><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>Lonardi</surname><given-names initials="S">Sara</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au19"><name name-style="western"><surname>Intini</surname><given-names initials="R">Rossana</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au20"><name name-style="western"><surname>Guarneri</surname><given-names initials="V">Valentina</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au21"><name name-style="western"><surname>Dieci</surname><given-names initials="MV">Maria Vittoria</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au22"><name name-style="western"><surname>Morabito</surname><given-names initials="A">Alberto</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au23"><name name-style="western"><surname>Barana</surname><given-names initials="D">Daniela</given-names></name><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au24"><name name-style="western"><surname>D'Urso</surname><given-names initials="A">Alessandra</given-names></name><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au25"><name name-style="western"><surname>Iafrate</surname><given-names initials="M">Massimo</given-names></name><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au26"><name name-style="western"><surname>Bergamo</surname><given-names initials="F">Francesca</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn2" ref-type="fn">o</xref></contrib><contrib contrib-type="author" id="au27"><name name-style="western"><surname>Urso</surname><given-names initials="EDL">Emanuele D.L.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn2" ref-type="fn">o</xref></contrib><aff id="aff1"><label>a</label>Third Surgery Unit, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padua, Padua, Italy</aff><aff id="aff2"><label>b</label>Familial Cancer Clinic and Oncoendocrinology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy</aff><aff id="aff3"><label>c</label>Medical Oncology Unit 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy</aff><aff id="aff4"><label>d</label>Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy</aff><aff id="aff5"><label>e</label>Department of Pathology, Azienda Ospedale Universit&#224; Padova, Padua, Italy</aff><aff id="aff6"><label>f</label>Department of Engineering for Innovative Medicine and Hospital of Trust of Verona, Oncology Section, Verona, Italy</aff><aff id="aff7"><label>g</label>General and Upper GI Surgery Unit, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy</aff><aff id="aff8"><label>h</label>Surgical Oncology of the Digestive Tract, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy</aff><aff id="aff9"><label>i</label>Medical Oncology Unit 2, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy</aff><aff id="aff10"><label>j</label>Department of Oncology, Azienda ULSS 6 &#8216;Euganea&#8217;, Cittadella, Italy</aff><aff id="aff11"><label>k</label>Oncology Unit, Local Health and Social Care Unit, ULSS8 Berica, Montecchio Maggiore, Italy</aff><aff id="aff12"><label>l</label>Pathology Unit, AULSS1 Dolomiti, Feltre, Italy</aff><aff id="aff13"><label>m</label>Urology Clinic, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. General Surgery 3, Department of Surgical, Oncological, and Gastroenterological Sciences, University of Padova, Via Giustiniani 2, 35128, Padua, Italy. <email>silvia.negro@unipd.it</email></corresp><fn id="fn1"><label>n</label><p id="ntpara0015">Co-First Authors: Silvia Negro, MD (Third Surgery Unit, University of Padua) and Francesco Celotto, MD (Third Surgery Unit, University of Padua).</p></fn><fn id="fn2"><label>o</label><p id="ntpara0020">Co-Senior Authors: Francesca Bergamo, MD (Medical Oncology Unit 1, IOV-IRCCS) and Emanuele Damiano Luca Urso, MD, PhD (Third Surgery Unit, University of Padua).</p></fn></author-notes><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2025</year></pub-date><volume>90</volume><issue-id pub-id-type="pmc-issue-id">500246</issue-id><elocation-id>103618</elocation-id><history><date date-type="received"><day>22</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>9</day><month>10</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>11</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-07 09:25:13.140"><day>07</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><title>Summary</title><sec><title>Background</title><p>Lynch syndrome (LS) is strongly associated with colorectal (CRC) and endometrial (EC) cancers, for which Universal Tumor Screening (UTS) via mismatch repair proteins (MMRs) immunohistochemistry is currently recommended. However, emerging evidence suggests an association between LS and several other tumor types. We therefore evaluate the incidence of non-CRC/ECs in LS individuals.</p></sec><sec><title>Methods</title><p>A retrospective analysis of 570 patients with LS diagnosed between 1995 and 2023 was performed (Ethics approval: AOP3125, July 27, 2023). Patients were stratified based on MMR gene mutations. Clinical data, including cancer type, age at diagnosis, and time to LS confirmation, were analyzed.</p></sec><sec><title>Findings</title><p>Non-CRC/ECs accounted for 40% (228/573) of all malignancies. The most common types were urothelial/kidney (8%), breast (8%), ovarian (6%) and gastric (4%) cancers. The highest SIRs were observed for cancers of the small intestine [SIR: 10.54; 95% CI: 5.90&#8211;17.39], urothelium/kidney [7.55; 95% CI: 5.42&#8211;10.24], gastric [4.68; 95% CI: 2.90&#8211;7.16], ovary [3.80; 95% CI: 2.32&#8211;5.87], and pancreas [3.09; 95% CI: 1.69&#8211;5.18]. Among the 63 (11%) patients diagnosed with non-CRC/ECs before genetic testing, 29 (46%) later developed CRC or EC, with a median time to onset of 10 years for CRC (IQR: 5&#8211;15) and 6 years for EC (IQR: 2&#8211;9).</p></sec><sec><title>Interpretation</title><p>The findings show that 40% of patients had non-CRC/ECs, with 11% of these cases diagnosed prior to undergoing genetic testing. Prospective studies with MMRs immunohistochemistry on all tumors arising in Lynch patients are needed to confirm our results and to explore the cost-effectiveness and feasibility of implementing broader screening strategies.</p></sec><sec><title>Funding</title><p>None.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Lynch syndrome</kwd><kwd>Universal tumor screening</kwd><kwd>Non-colorectal/endometrial tumors</kwd><kwd>Extracolonic malignancies</kwd><kwd>Mismatch repair genes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Research in context</title></caption><sec id="dtbox1sec1"><title>Evidence before this study</title><p id="p0015">Before conducting our retrospective analysis, we systematically reviewed studies in PubMed up to August 30, 2024, focused on Lynch syndrome and its associated cancer risks beyond colorectal (CRC) and endometrial cancers (EC). Previous research predominantly highlights CRC and EC as hallmark malignancies of LS, with Universal Tumor Screening (UTS) via mismatch repair protein (MMR) immunohistochemistry primarily targeted at these cancer types. Emerging evidence has suggested potential links between LS and other malignancies, including urothelial, ovarian, gastric, pancreatic, and skin cancers.</p></sec><sec id="dtbox1sec2"><title>Added value of this study</title><p id="p0020">This study presents a large-scale retrospective analysis of 570 LS patients diagnosed between 1995 and 2023, providing robust evidence of the prevalence and impact of non-CRC/ECs in individuals with LS. The findings reveal that 40% of patients presented with non-CRC/ECs, with a subset of 11% diagnosed with these malignancies prior to genetic testing. Notably, a significant proportion of these patients subsequently developed CRC or EC, underscoring the missed opportunity for early LS diagnosis under current screening protocols.</p></sec><sec id="dtbox1sec3"><title>Implications of all the available evidence</title><p id="p0025">Our findings, if validated by prospective studies with MMRs testing, may suggest that expanding UTS to include additional cancer types&#8212;such as urothelial, ovarian, gastro-jejunal, pancreatic, and skin cancers&#8212; could lead to earlier detection and improved clinical outcomes in individuals with LS, particularly those under the age of 50.</p></sec></boxed-text>
</p><sec id="sec1"><title>Introduction</title><p id="p0030">Lynch syndrome (LS) is an autosomal dominant disorder caused by pathogenic germline variants in one of the four DNA mismatch repair (MMR) genes: <italic toggle="yes">MLH1, MSH2, MSH6, or PMS2</italic> and, rarely, in the non-MMR gene <italic toggle="yes">EPCAM</italic>, where deletions induce epigenetic silencing of <italic toggle="yes">MSH2</italic>.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> LS is responsible for approximately 3% of colorectal cancer (CRC) cases and 2% of endometrial cancer (EC) cases.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> The cumulative lifetime penetrance, defined as the probability of developing a LS-related malignancy over a lifetime, is estimated to be 70%, depending on the specific gene mutation.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref> Historically, the Amsterdam criteria and Bethesda guidelines have provided structured methods for identifying LS based on familial aggregation and/or early-onset cancers.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> However, these clinical criteria are estimated to miss around 28% of individuals with LS, highlighting the limitations of traditional diagnostic approaches.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> To address underdiagnosis, the Universal Tumor Screening (UTS) was introduced, whereby all newly diagnosed cases of CRC and EC cases are routinely tested for MMR deficiency (dMMR) or high-level microsatellite instability (MSI-H).<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref></p><p id="p0035">According to UTS, all cases of CRC and EC should undergo immunohistochemical (IHC) analysis for the MMR proteins: MLH1, MSH2, MSH6 and PMS2. A negative staining result for MSH2, MSH6, or PMS2 on IHC warrants genetic counseling as it suggests a possible germline mutation in one of these genes. However, in cases with MLH1 loss of expression, further testing is required due to the possibility of somatic MLH1 promoter hypermethylation, a common non-hereditary cause of MLH1 inactivation. Traditionally, the presence of a BRAF V600E mutation in CRC rules out MLH1 deficiency related to LS.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Therefore, in cases where MLH1 is negative on IHC, BRAF V600E mutation testing and/or MLH1 promoter methylation analysis should be performed before genetic counseling for LS is considered. Identification of BRAF V600E or MLH1 promoter hypermethylation suggests that the MLH1 loss is likely to be sporadic and not due to LS. However, recent evidence suggests that BRAF V600E testing may not reliably exclude LS in younger patients. A review of 969 MSI CRCs in individuals with LS found BRAF mutations in 1.6%, with most cases (6/7) occurring in patients younger than 50 years. In contrast, only 0.6% of BRAF-mutant CRCs in unselected MSI cases were under 50 years of age. This suggests the need for age-specific considerations in LS screening protocols.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> The primary goal of UTS is to identify patients with LS and to ensure appropriate genetic counseling and risk management for affected families. In addition to CRC and EC, several other neoplasms are recognized within the LS spectrum, including ovarian (lifetime risk: 1&#8211;38%), gastric and small bowel (1&#8211;13%), urinary tract (1&#8211;18%), pancreatic (1&#8211;6%), biliary (1&#8211;4%), brain (1&#8211;5%), skin (1&#8211;9%), and breast (8&#8211;13%) cancers.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> However, the current UTS algorithm does not include screening for these non-CRC/ECs, thus invalidating or delaying the identification of patients with LS whose first cancer manifestation involves other LS-associated tumors. Furthermore, surveillance guidelines for non-CRC/ECs remain fragmented and often inconsistent across international societies, resulting in postponements of early diagnosis and suboptimal disease management.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> The prevalence of LS in the general population is estimated to be 1 in 279 (mutation-specific frequencies of 1 in 1946 for <italic toggle="yes">MLH1</italic><bold>,</bold> 1 in 2841 for <italic toggle="yes">MSH2</italic><bold>,</bold> 1 in 758 for <italic toggle="yes">MSH6</italic><bold>,</bold> and 1 in 714 for <italic toggle="yes">PMS2</italic>).<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> These figures make LS as one of the most common inherited cancer predisposition syndromes, emphasizing the need for accurate and comprehensive identification strategies. In an effort to maximize the detection rate in the general population, this study aims to explore the role of non-CRC/ECs, especially when they occur as the first tumor in individuals with LS. The secondary objective is to analyze the relationship between specific genotypes and the risk of developing non-CRC/ECs, with the aim of expanding current surveillance guidelines and improving early diagnosis strategies.</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Patient selection and data collection</title><p id="p0040">All consecutive patients with LS enrolled at the Hereditary Gastrointestinal Cancer Unit of the University Hospital of Padua (AOUPD) and the Veneto Institute of Oncology (IOV) between January 1995 and June 2023 were retrospectively evaluated for inclusion in the study. Inclusion criteria were the following: a confirmed diagnosis of germline pathogenic variants (GPVs) (class 4 or 5) in the <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>, <italic toggle="yes">PMS2</italic>, or <italic toggle="yes">EPCAM</italic> genes<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>; a minimum follow-up period of one year; the availability of medical records with clinical information updated to at least 2020. Patients were excluded if they had a prior diagnosis of LS based on the Amsterdam II criteria without a confirmed molecular diagnosis, a germline variant of uncertain significance (class 3) in mismatch repair (MMR) genes, outdated clinical records, or a follow-up period of less than one year. Patients meeting the inclusion criteria were divided into five groups based on the results of the genetic study: carriers of GPVs of the <italic toggle="yes">MLH1</italic> gene (<italic toggle="yes">MLH1</italic> group), carriers of GPVs of the <italic toggle="yes">MSH2</italic> gene (<italic toggle="yes">MSH2</italic> group), carriers of GPVs of the <italic toggle="yes">MSH6</italic> gene (<italic toggle="yes">MSH6</italic> group), carriers of GPVs of the <italic toggle="yes">PMS2</italic> gene (<italic toggle="yes">PMS2</italic> group), and carriers of GPVs of the <italic toggle="yes">EPCAM</italic> gene (<italic toggle="yes">EPCAM</italic> group). Although EPCAM gene mutations disrupt MSH2 function and lead to its silencing, we chose to analyze the two groups separately. This decision is justified by their distinct genetic and clinical characteristics. Patients with <italic toggle="yes">EPCAM</italic> deletions tend to develop tumors predominantly in tissues with high <italic toggle="yes">EPCAM</italic> expression, such as the intestinal epithelium, while <italic toggle="yes">MSH2</italic> mutations are associated with a broader tumor spectrum.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Furthermore, <italic toggle="yes">EPCAM</italic> deletions account for a smaller proportion of cases of LS (&#8764;3%) and are associated with distinct cancer risks, including a lower risk of endometrial cancer compared to <italic toggle="yes">MSH2</italic> mutation carriers.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Clinicopathological data of the enrolled patients included age, sex, age at LS diagnosis (defined as the age at genetic testing), personal history of CRC/ECs and non-CRC/ECs, age of cancers onset, and date of last follow-up or death. Clinical and pathological tumors staging were collected or revised using the American Joint Committee on Cancer (AJCC) staging system, 8th edition.</p></sec><sec id="sec2.2"><title>Ethics</title><p id="p0045">This study was approved by the Ethical Committee of IOV-AOUPD (approval number, AOP3125, July 27, 2023), conducted according to the principles of the Helsinki Declaration, and all patients gave their written consent for inclusion in the study. Consent for genetic testing also included approval for the anonymized use of clinical and molecular data for research purposes. For deceased patients, data were obtained from medical records previously authorized for research use.</p></sec><sec id="sec2.3"><title>Genetic analysis</title><p id="p0050">After genetic counseling, a peripheral blood sample was collected for each patient. DNA was extracted from whole blood, and mutational analysis for MMR genes was performed. Molecular testing was performed using a next-generation sequencing (NGS) multigene panel, utilizing the QiaSeq FX DNA library preparation kit (Qiagen) and target enrichment with IDT&#174; probes. Sequencing was conducted on the Illumina MiSeq platform with a 600-cycle MiSeq Reagent Kit v3<bold>,</bold> ensuring comprehensive coverage of coding regions and exon-intron junctions (&#177;25 bases) for a broad spectrum of genes associated with hereditary cancer syndromes. The NGS panel allowed for the detection of: single nucleotide variants (SNVs) and small insertions/deletions (indels)<bold>,</bold> copy number variations (CNVs) (deletions/duplications)<bold>,</bold> and mosaic variants with an allele frequency &gt;5% (for selected genes). Variant classification followed guidelines from ClinGen, ACMG, and AMP, with nomenclature standardized according to HGVS recommendations.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Identified variants were confirmed using Sanger sequencing, MLPA, real-time PCR, or CGH array, when required. The test achieved a concordance rate &gt;99.9% in internal validation, demonstrating high accuracy and clinical reliability. All sequence variants were reclassified by two geneticists (F.S. and S.R.) according to the recommendations of the American College of Medical Genetics and Genomics.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Our laboratory also regularly participates in the external quality control (VEQ) programmes of the European Molecular Genetic Quality Network (EMQN). For detailed information, see <xref rid="appsec1" ref-type="sec">Supplementary Genetic Analysis</xref>.</p></sec><sec id="sec2.4"><title>Statistical analysis</title><p id="p0055">Categorical data were described as totals and frequencies, while continuous data were described as medians and interquartile ranges. Fisher's exact test and the &#967;<sup>2</sup> test were used to compare categorical variables. Specifically, the &#967;<sup>2</sup> test was used when all expected cell counts were &#8805;5, while Fisher's exact test was used when this assumption was violated, ensuring appropriate statistical validity for small sample sizes or low expected frequencies. Continuous variables were analyzed with the Wilcoxon rank-sum test, as the assumption of normality, assessed using Shapiro&#8211;Wilk test, was not consistently met across groups (<xref rid="appsec1" ref-type="sec">Supplementary Statistical Analysis</xref>). Standardized incidence ratios (SIRs), adjusted for age, sex, and country (Europe), with 95% confidence intervals (CIs) were calculated to compare cancer-specific incidence rates between the LS cohort and the general population. SIRs were obtained by dividing the number of observed cancer cases in the study cohort by the number expected for each age group based on incidence rates in the general population. Population estimates were derived from the Global Cancer Observatory (GLOBOCAN) and Surveillance, Epidemiology, and End Results (SEER) Program Databases.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Exact 95% confidence intervals were calculated assuming that the observed number of cancers followed a Poisson distribution. All tests were two-sided, with a significance level set at P &lt; 0.05. Statistical analyses were conducted using GraphPad Prism software (version 10.4.1). Given the multiple comparisons performed in this study, we recognize the potential issue of Type I error inflation. However, as this study is exploratory in nature, we did not apply a formal multiplicity adjustment.</p></sec><sec id="sec2.5"><title>Role of funding source</title><p id="p0060">This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The funders had no role in study design, data collection, data analyses, interpretation, or writing of the report.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Clinicopathological characteristics of LS patients</title><p id="p0065">Between 1995 and 2023, a total of 570 patients with LS were identified (<xref rid="tbl1" ref-type="table">Table 1</xref>). Of these, 336 (59%) were female, with a median age at diagnosis of LS of 50 years (y) (IQR:38&#8211;61).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>LS patients&#8217; clinicopathological characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Overall (n = 570)</th><th colspan="1" rowspan="1">MLH1 (n = 167)</th><th colspan="1" rowspan="1">MSH2 (n = 273)</th><th colspan="1" rowspan="1">MSH6 (n = 72)</th><th colspan="1" rowspan="1">PMS2 (n = 47)</th><th colspan="1" rowspan="1">EPCAM (n = 11)</th><th colspan="1" rowspan="1">P-value</th><th colspan="1" rowspan="1">P-value MLH1 vs. MSH2</th><th colspan="1" rowspan="1">P-value MLH1 vs. MSH6</th><th colspan="1" rowspan="1">P-value MLH1 vs. PMS2</th><th colspan="1" rowspan="1">P-value MLH1 vs. EPCAM</th><th colspan="1" rowspan="1">P-value MSH2 vs. MSH6</th><th colspan="1" rowspan="1">P-value MSH2 vs. PMS2</th><th colspan="1" rowspan="1">P-value MSH2 vs. EPCAM</th><th colspan="1" rowspan="1">P-value MSH6 vs. PMS2</th><th colspan="1" rowspan="1">P-value MSH6 vs. EPCAM</th><th colspan="1" rowspan="1">P-value PMS2 vs. EPCAM</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sex (N (%))</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1">234 (41)</td><td colspan="1" rowspan="1">79 (47)</td><td colspan="1" rowspan="1">112 (41)</td><td colspan="1" rowspan="1">25 (35)</td><td colspan="1" rowspan="1">12 (25)</td><td colspan="1" rowspan="1">6 (54)</td><td align="char" colspan="1" rowspan="1">0.0036</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.077</td><td colspan="1" rowspan="1">0.00031</td><td colspan="1" rowspan="1">0.75</td><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">0.0025</td><td colspan="1" rowspan="1">0.53</td><td colspan="1" rowspan="1">0.081</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">0.023</td></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="1" rowspan="1">336 (59)</td><td colspan="1" rowspan="1">88 (53)</td><td colspan="1" rowspan="1">161 (59)</td><td colspan="1" rowspan="1">47 (65)</td><td colspan="1" rowspan="1">35 (75)</td><td colspan="1" rowspan="1">5 (46)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age at LS diagnosis (years; Median [IQR])</td><td colspan="1" rowspan="1">50 [38&#8211;51]</td><td colspan="1" rowspan="1">44 [33&#8211;54]</td><td colspan="1" rowspan="1">51 [36&#8211;61]</td><td colspan="1" rowspan="1">57 [41&#8211;70]</td><td colspan="1" rowspan="1">53 [43&#8211;70]</td><td colspan="1" rowspan="1">41 [34&#8211;62]</td><td align="char" colspan="1" rowspan="1">0.00028</td><td colspan="1" rowspan="1">0.022</td><td colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">0.0014</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">0.051</td><td colspan="1" rowspan="1">0.55</td><td colspan="1" rowspan="1">0.67</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">0.12</td></tr><tr><td colspan="1" rowspan="1">Tumor type (N (%))</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;CRC</td><td colspan="1" rowspan="1">250 (44)</td><td colspan="1" rowspan="1">100 (60)</td><td colspan="1" rowspan="1">116 (42)</td><td colspan="1" rowspan="1">17 (24)</td><td colspan="1" rowspan="1">12 (25)</td><td colspan="1" rowspan="1">5 (45)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">0.00045</td><td colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">0.0041</td><td colspan="1" rowspan="1">0.034</td><td colspan="1" rowspan="1">0.022</td><td colspan="1" rowspan="1">&gt;0.99</td><td colspan="1" rowspan="1">0.88</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.27</td></tr><tr><td colspan="1" rowspan="1">&#160;EC</td><td colspan="1" rowspan="1">95 (17)</td><td colspan="1" rowspan="1">20 (12)</td><td colspan="1" rowspan="1">55 (20)</td><td colspan="1" rowspan="1">12 (17)</td><td colspan="1" rowspan="1">5 (11)</td><td colspan="1" rowspan="1">3 (27)</td><td align="char" colspan="1" rowspan="1">0.11<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">&#160;Non CRC/EC</td><td colspan="1" rowspan="1">228 (40)</td><td colspan="1" rowspan="1">59 (35)</td><td colspan="1" rowspan="1">134 (49)</td><td colspan="1" rowspan="1">16 (22)</td><td colspan="1" rowspan="1">13 (27)</td><td colspan="1" rowspan="1">6 (54)</td><td align="char" colspan="1" rowspan="1">0.00040</td><td colspan="1" rowspan="1">0.0079</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.32</td><td colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1">0.00040</td><td colspan="1" rowspan="1">0.0087</td><td colspan="1" rowspan="1">0.76</td><td colspan="1" rowspan="1">0.76</td><td colspan="1" rowspan="1">0.080</td><td colspan="1" rowspan="1">0.15</td></tr><tr><td colspan="1" rowspan="1">Age at tumor diagnosis (years; Median [IQR])</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;CRC</td><td colspan="1" rowspan="1">47 [40&#8211;56]</td><td colspan="1" rowspan="1">44 [37&#8211;51]</td><td colspan="1" rowspan="1">49 [41&#8211;58]</td><td colspan="1" rowspan="1">60 [40&#8211;71]</td><td colspan="1" rowspan="1">63 [48&#8211;78]</td><td colspan="1" rowspan="1">39 [29&#8211;63]</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">0.0012</td><td colspan="1" rowspan="1">0.0054</td><td colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">0.78</td><td colspan="1" rowspan="1">0.096</td><td colspan="1" rowspan="1">0.0035</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">0.45</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">0.051</td></tr><tr><td colspan="1" rowspan="1">&#160;EC</td><td colspan="1" rowspan="1">51 [42&#8211;56]</td><td colspan="1" rowspan="1">49 [41&#8211;54]</td><td colspan="1" rowspan="1">50 [40&#8211;55]</td><td colspan="1" rowspan="1">55 [53&#8211;63]</td><td colspan="1" rowspan="1">62 [45&#8211;66]</td><td colspan="1" rowspan="1">46 [39&#8211;55]</td><td align="char" colspan="1" rowspan="1">0.012</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">0.0038</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">0.66</td><td colspan="1" rowspan="1">0.0031</td><td colspan="1" rowspan="1">0.084</td><td colspan="1" rowspan="1">0.74</td><td colspan="1" rowspan="1">0.55</td><td colspan="1" rowspan="1">0.079</td><td colspan="1" rowspan="1">0.25</td></tr><tr><td colspan="1" rowspan="1">&#160;Non CRC/EC</td><td colspan="1" rowspan="1">53 [41&#8211;62]</td><td colspan="1" rowspan="1">51 [39&#8211;58]</td><td colspan="1" rowspan="1">52 [41&#8211;60]</td><td colspan="1" rowspan="1">62 [55&#8211;71]</td><td colspan="1" rowspan="1">56 [53&#8211;64]</td><td colspan="1" rowspan="1">46 [33&#8211;54]</td><td align="char" colspan="1" rowspan="1">0.061</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">Pts with no tumor diagnosis (N (%))</td><td colspan="1" rowspan="1">209 (37)</td><td colspan="1" rowspan="1">50 (30)</td><td colspan="1" rowspan="1">92 (34)</td><td colspan="1" rowspan="1">39 (54)</td><td colspan="1" rowspan="1">27 (57)</td><td colspan="1" rowspan="1">1 (9)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">0.41</td><td colspan="1" rowspan="1">0.00045</td><td colspan="1" rowspan="1">0.00052</td><td colspan="1" rowspan="1">0.18<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">0.0017</td><td colspan="1" rowspan="1">0.0011</td><td colspan="1" rowspan="1">0.10<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">0.0072<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">0.0059<xref rid="tbl1fna" ref-type="table-fn">a</xref></td></tr><tr><td colspan="1" rowspan="1">F.up (months; Median [IQR])</td><td colspan="1" rowspan="1">72 [36&#8211;164]</td><td colspan="1" rowspan="1">108 [36&#8211;216]</td><td colspan="1" rowspan="1">72 [36&#8211;180]</td><td colspan="1" rowspan="1">36 [14&#8211;72]</td><td colspan="1" rowspan="1">36 [16&#8211;72]</td><td colspan="1" rowspan="1">108 [54&#8211;171]</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">0.54</td><td colspan="1" rowspan="1">&lt;0.0001</td><td colspan="1" rowspan="1">0.00021</td><td colspan="1" rowspan="1">0.85</td><td colspan="1" rowspan="1">0.00028</td><td colspan="1" rowspan="1">0.00059</td><td colspan="1" rowspan="1">0.85</td><td colspan="1" rowspan="1">0.83</td><td colspan="1" rowspan="1">0.0071</td><td colspan="1" rowspan="1">0.0078</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: LS: Lynch Syndrome; CRC: Colorectal Cancer; EC: Endometrial Cancer; F.up: Follow up; Pts: Patients; non-CRC/EC: non-colorectal/endometrial cancer; IQR: interquartile range.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0025">P values were calculated with the use of the Fisher's exact test.</p></fn></table-wrap-foot></table-wrap></p><p id="p0070">Among the entire cohort and at any time in the personal history, 44% (n = 250) of patients had a diagnosis of CRC, 17% (n = 95) EC and 40% (n = 228) non-CRC/ECs, respectively (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The median age of cancer onset was 47 y (40&#8211;56 y) for CRC, 51 y (42&#8211;56 y) for EC and 53 y (41&#8211;62 y) for non-CRC/ECs. The median follow-up time was 72 months (IQR: 36&#8211;164).<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Distribution of tumor types in Lynch syndrome (LS) cohort</bold>. Proportions of colorectal cancer (CRC), endometrial cancer (EC), and non-colorectal/endometrial cancer (non-CRC/EC). Abbreviations: LS, Lynch syndrome; CRC, colorectal cancer; EC, endometrial cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0075">The distribution of patients among the GPVs subgroups was as follows: 167 (29%) in the <italic toggle="yes">MLH1</italic> group, 273 (48%) in the <italic toggle="yes">MSH2</italic> group, 72 (13%) in the <italic toggle="yes">MSH6</italic> group, 47 (8%) in the <italic toggle="yes">PMS2</italic> group and 11 (2%) in the <italic toggle="yes">EPCAM</italic> group. Females were the most affected sex across all groups except for the <italic toggle="yes">EPCAM</italic> group (males n = 6 vs. females n = 5). The <italic toggle="yes">PMS2</italic> group had the highest proportion of females (75%) compared to <italic toggle="yes">MLH1</italic> (53%), <italic toggle="yes">MSH2</italic> (59%), and <italic toggle="yes">EPCAM</italic> (46%) (P = 0.0036). The median age at diagnosis of LS was significantly lower in the <italic toggle="yes">MLH1</italic> group (44 y) compared to <italic toggle="yes">MSH6</italic> (57 y) and <italic toggle="yes">PMS2</italic> (53 y) (P = 0.00028). Patients in the <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> groups had a significantly higher incidence of CRC compared to <italic toggle="yes">MSH6</italic> and <italic toggle="yes">PMS2</italic> groups (60% and 42% vs. 24% and 25%, respectively, P &lt; 0.0001). The median age at CRC diagnosis was significantly lower for the <italic toggle="yes">MLH1</italic> group (44 y) compared to <italic toggle="yes">MSH2</italic> (49 y), <italic toggle="yes">MSH6</italic> (60 y) and <italic toggle="yes">PMS2</italic> (63 y) (P &lt; 0.0001). There were no significant differences in EC rates among the five groups, with EC risk ranging from 11% for the <italic toggle="yes">PMS2</italic> to 27% for the <italic toggle="yes">EPCAM</italic> group. The age at diagnosis of EC was lower for <italic toggle="yes">MLH1</italic> (49 y) and <italic toggle="yes">MSH2</italic> (50 y) compared to <italic toggle="yes">MSH6</italic> (55 y) (P = 0.012). For non-CRC/ECs, the reported risk ranged from 22% for the <italic toggle="yes">MSH6</italic> to 54% in the <italic toggle="yes">EPCAM</italic> group. The <italic toggle="yes">MSH2</italic> group exhibited a significantly higher risk of non-CRC/ECs compared to <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH6</italic> and <italic toggle="yes">PMS2</italic> groups (49% vs. 35% and 22% and 27% respectively, P = 0.00043). No significant differences were observed between the five groups with respect to the age of onset of non-CRC/ECs. Overall, 37% of the carriers of a pathogenic variant had never been diagnosed with cancer. The highest proportions were observed in the <italic toggle="yes">PMS2</italic> (57%) and <italic toggle="yes">MSH6</italic> (54%) groups, compared to MLH1 (30%), MSH2 (34%) and EPCAM (9%, P &lt; 0.0001).</p><p id="p0080">The median follow-up was significantly longer in the MLH1, MSH2 and EPCAM groups (108 vs. 72 months vs. 108 months, respectively) compared to the MSH6 and PMS2 groups (36 months each; P &lt; 0.0001).</p></sec><sec id="sec3.2"><title>Non-CRC/ECs</title><p id="p0085">The distribution of non-CRC/ECs and their association with different genotypes is shown in <xref rid="tbl2" ref-type="table">Table 2</xref>. The most frequently reported non-CRC/ECs were urothelial/kidney cancer (8%, 44 patients), breast cancer (8%, 26 patients in the female population), gastric cancer (4%, 21 patients), and ovarian cancer (6%, 21 patients in the female population). Other cancer types, including skin (3%, 17 patients), small bowel (3%, 16 patients), pancreas (3%, 16 patients), brain (3%, 15 patients), thyroid (3%, 14 patients) and prostate (3%, 8 patients in the male population) were less common. Bladder, pulmonary, sarcoma, cholangiocarcinoma, testis, lymphoma, and gallbladder cancers, accounted for 0.2&#8211;1% of cases each. Urothelial/Kidney cancer was most frequently observed in the <italic toggle="yes">MSH2</italic> group (13%, 35 patients), followed by the <italic toggle="yes">EPCAM</italic> group (27%, 3 patients). A small number of cases were identified in the <italic toggle="yes">MLH1</italic> group (2%, 4 patients) and <italic toggle="yes">MSH6</italic> group (3%, 2 patients). Breast cancer was predominantly seen in the <italic toggle="yes">PMS2</italic> group (14%, 5 patients in the female population) and <italic toggle="yes">MLH1</italic> group (9%, 8 patients in the female population). The other groups, <italic toggle="yes">MSH2</italic> and <italic toggle="yes">MSH6</italic>, exhibited lower frequencies of breast cancer at 7% and 4%, respectively. Gastric cancer was more common in the <italic toggle="yes">MSH2</italic> group (5%, 13 patients), <italic toggle="yes">MLH1</italic> (3%, 5 patients) and <italic toggle="yes">MSH6</italic> groups (3%, 2 patients), with lower frequencies in the <italic toggle="yes">PMS2</italic> group (2%, 1 patients). Ovarian cancer was most frequently observed in the <italic toggle="yes">MSH2</italic> (9%, 15 patients in the female population), with fewer cases in the <italic toggle="yes">MLH1</italic> group (6%, 5 patients in the female population) and <italic toggle="yes">MSH6</italic> group (2%, 1 patient in the female population). Skin cancer was more common in the <italic toggle="yes">PMS2</italic> group (6%, 3 patients), <italic toggle="yes">MSH2</italic> (3%, 8 patients) and <italic toggle="yes">MLH1</italic> group (3%, 5 patients). Other cancers, including testis, lymphoma and gallbladder were observed sporadically across the subgroups. The median age at diagnosis for non-CRC/ECs varied significantly across cancer types. Among the most frequent cancers, ovarian were diagnosed at the youngest median age (41 y, IQR: 38&#8211;46), followed by brain cancers (43 y, IQR: 25&#8211;56) and thyroid cancers (43 y, IQR: 29&#8211;62). The oldest median ages were reported for pulmonary cancers (73 y, IQR: 55&#8211;75) and prostate cancers (63 y, IQR: 56&#8211;73).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Non-CRC/ECs in LS patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Non-CRC/EC cancer type</th><th colspan="1" rowspan="1">Overall (n = 570)</th><th colspan="1" rowspan="1">MLH1 (n = 167)</th><th colspan="1" rowspan="1">MSH2 (n = 273)</th><th colspan="1" rowspan="1">MSH6 (n = 72)</th><th colspan="1" rowspan="1">PMS2 (n = 47)</th><th colspan="1" rowspan="1">EPCAM (n = 11)</th><th colspan="1" rowspan="1">Age at diagnosis (years; Median [IQR])</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Urothelium/kidney (N (%))</td><td colspan="1" rowspan="1">44 (8%)</td><td colspan="1" rowspan="1">2 (M), 2 (F) = 4 (2%)</td><td colspan="1" rowspan="1">15 (M), 20 (F) = 35 (13%)</td><td colspan="1" rowspan="1">2 (F) = 2 (3%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 (M), 1 (F) = 3 (27%)</td><td colspan="1" rowspan="1">56 [51&#8211;69]</td></tr><tr><td colspan="1" rowspan="1">Breast (N (%))</td><td colspan="1" rowspan="1">26 (8% in the female population)</td><td colspan="1" rowspan="1">8 (F) = 8 (9% in the female population)</td><td colspan="1" rowspan="1">11 (F) = 11 (7% in the female population)</td><td colspan="1" rowspan="1">2 (F) = 2 (4% in the female population)</td><td colspan="1" rowspan="1">5 (F) = 5 (14% in the female population)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">55 [49&#8211;61]</td></tr><tr><td colspan="1" rowspan="1">Gastric (N (%))</td><td colspan="1" rowspan="1">21 (4%)</td><td colspan="1" rowspan="1">3 (M), 2 (F) = 5 (3%)</td><td colspan="1" rowspan="1">9 (M), 4 (F) = 13 (5%)</td><td colspan="1" rowspan="1">1 (M) 1 (F) = 2 (3%)</td><td colspan="1" rowspan="1">1 (F) = 1 (2%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">58 [44&#8211;68]</td></tr><tr><td colspan="1" rowspan="1">Ovarian (N (%))</td><td colspan="1" rowspan="1">21 (6% in the female population)</td><td colspan="1" rowspan="1">5 (F) = 5 (6% in the female population)</td><td colspan="1" rowspan="1">15 (F) = 15 (9% in the female population)</td><td colspan="1" rowspan="1">1 (F) = 1 (2% in the female population)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">41 [38&#8211;46]</td></tr><tr><td colspan="1" rowspan="1">Skin<xref rid="tbl2fna" ref-type="table-fn">a</xref> (N (%))</td><td colspan="1" rowspan="1">17 (3%)</td><td colspan="1" rowspan="1">1 (M), 4 (F) = 5 (3%)</td><td colspan="1" rowspan="1">4 (M), 4 (F) = 8 (3%)</td><td colspan="1" rowspan="1">1 (F) = 1 (1%)</td><td colspan="1" rowspan="1">1 (M), 2 (F) = 3 (6%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">60 [53&#8211;69]</td></tr><tr><td colspan="1" rowspan="1">Small Bowel<xref rid="tbl2fnb" ref-type="table-fn">b</xref> (N (%))</td><td colspan="1" rowspan="1">16 (3%)</td><td colspan="1" rowspan="1">1 (M), 4 (F) = 5 (3%)</td><td colspan="1" rowspan="1">5 (M), 5 (F) = 10 (4%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 (F) = 1 (2%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">56 [42&#8211;67]</td></tr><tr><td colspan="1" rowspan="1">Pancreas (N (%))</td><td colspan="1" rowspan="1">16 (3%)</td><td colspan="1" rowspan="1">5 (M), 3 (F) = 8 (5%)</td><td colspan="1" rowspan="1">5 (F) = 5 (2%)</td><td colspan="1" rowspan="1">2 (M) 1 (F) = 3 (5%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">59 [55&#8211;63]</td></tr><tr><td colspan="1" rowspan="1">Brain (N (%))</td><td colspan="1" rowspan="1">15 (3%)</td><td colspan="1" rowspan="1">5 (M), 2 (F) = 7 (4%)</td><td colspan="1" rowspan="1">3 (M), 3 (F) = 6 (2%)</td><td colspan="1" rowspan="1">1 (F) = 1 (1%)</td><td colspan="1" rowspan="1">1 (F) = 1 (2%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">43 [25&#8211;56]</td></tr><tr><td colspan="1" rowspan="1">Thyroid (N (%))</td><td colspan="1" rowspan="1">14 (3%)</td><td colspan="1" rowspan="1">1 (M), 2 (F) = 3 (2%)</td><td colspan="1" rowspan="1">2 (M), 5 (F) = 7 (3%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 (M) = 1 (2%)</td><td colspan="1" rowspan="1">2 (M), 2 (F) = 3 (27%)</td><td colspan="1" rowspan="1">43 [29&#8211;62]</td></tr><tr><td colspan="1" rowspan="1">Prostate (N (%))</td><td colspan="1" rowspan="1">8 (3% in the male population)</td><td colspan="1" rowspan="1">1 (M) = 1 (1% in the male population)</td><td colspan="1" rowspan="1">7 (M) = 7 (6% in the male population)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">63 [56&#8211;73]</td></tr><tr><td colspan="1" rowspan="1">Bladder (N (%))</td><td colspan="1" rowspan="1">7 (1%)</td><td colspan="1" rowspan="1">1 (M) = 1 (1%)</td><td colspan="1" rowspan="1">2 (M), 4 (F) = 6 (2%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">58 [51&#8211;72]</td></tr><tr><td colspan="1" rowspan="1">Pulmonary (N (%))</td><td colspan="1" rowspan="1">6 (1%)</td><td colspan="1" rowspan="1">1 (M), 2 (F) = 3 (2%)</td><td colspan="1" rowspan="1">1 (F) = 1 (0.4%)</td><td colspan="1" rowspan="1">1 (M) 1 (F) = 2 (3%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">73 [55&#8211;75]</td></tr><tr><td colspan="1" rowspan="1">Sarcoma (N (%))</td><td colspan="1" rowspan="1">6 (1%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">6 (M) = 6 (2%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">30 [20&#8211;59]</td></tr><tr><td colspan="1" rowspan="1">Cholangiocarcinoma (N (%))</td><td colspan="1" rowspan="1">6 (1%)</td><td colspan="1" rowspan="1">2 (M), 1 (F) = 3 (2%)</td><td colspan="1" rowspan="1">1 (M) = 3 (1%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">56 [51&#8211;70]</td></tr><tr><td colspan="1" rowspan="1">Testis (N (%))</td><td colspan="1" rowspan="1">2 (0.3%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 (M) = 1 (0.4%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 (M) = 1 (2%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">31 [24&#8211;38]</td></tr><tr><td colspan="1" rowspan="1">Lymphoma (N (%))</td><td colspan="1" rowspan="1">2 (0.3%)</td><td colspan="1" rowspan="1">1 (M) = 1 (1%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 (F) = 1 (1%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">40 [28&#8211;51]</td></tr><tr><td colspan="1" rowspan="1">Gallbladder (N (%))</td><td colspan="1" rowspan="1">1 (0.2%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">1 (F) = 1 (1%)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">62</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1"><bold>228 (40%)</bold></td><td colspan="1" rowspan="1"><bold>59 (35%)</bold></td><td colspan="1" rowspan="1"><bold>134 (49%)</bold></td><td colspan="1" rowspan="1"><bold>16 (22%)</bold></td><td colspan="1" rowspan="1"><bold>13 (27%)</bold></td><td colspan="1" rowspan="1"><bold>6 (54%)</bold></td><td colspan="1" rowspan="1"><bold>53 [41</bold>&#8211;<bold>62]</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: M: male; F: female; CRC: Colorectal Cancer; EC: Endometrial Cancer; IQR: interquartile range.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0030">Includes melanoma (5 cases) and sebaceous neoplasms (12 cases).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0035">Includes adenocarcinoma of the duodenum and jejunum (13 cases), and ileum.</p></fn></table-wrap-foot></table-wrap></p><p id="p0090">Overall, several cancer types showed a significantly increased incidence compared to the general population, as indicated by the SIRs calculated for individuals aged 14 to 85+ years (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). The highest SIRs were observed for small intestine [10.54, 95% CI: 5.90&#8211;17.39], urothelium/kidney [7.55, 95% CI: 5.42&#8211;10.24], gastric cancer [4.68, 95% CI: 2.90&#8211;7.16], ovarian cancer [3.80, 95% CI: 2.32&#8211;5.87] and pancreatic cancer [3.09, 95% CI: 1.69&#8211;5.18]. A moderate but statistically significant increase was observed for thyroid cancer [2.81, 95% CI: 1.45&#8211;4.90]. Brain cancer cases were excluded from the SIR analysis because the histologic subtype was not known in all cases. Less common cancers in our cohort, such cholangiocarcinoma, testicular cancer, lymphoma and gallbladder cancer, were also excluded from the analysis.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Standardized Incidence Ratio (SIR) for the age 14</bold>&#8211;<bold>85+ for all malignancies in LS cohort compared with the general population</bold>. Dots represent the SIR values; error bars indicate 95% confidence intervals (CIs). SIRs were calculated by dividing the observed number of cancers in the LS cohort by the expected number based on population-specific incidence rates (GLOBOCAN and SEER data). Abbreviations: LS, Lynch syndrome; CRC, colorectal cancer; EC, endometrial cancer; SIR, standardized incidence ratio; CI, confidence interval.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec3.3"><title>Timing and distribution of non-CRC/ECs</title><p id="p0095">The timing and distribution of non-CRC/ECs are shown in <xref rid="tbl3" ref-type="table">Table 3</xref> and <xref rid="fig3" ref-type="fig">Fig. 3</xref>. Among the 228 non-CRC/ECs analyzed, 98 (17% of the whole cohort and 43% of the non-CRC/EC group) occurred as the first cancer manifestation in patients with LS. Of these, 63 cases (64%) were diagnosed before the diagnosis of LS: in these cases, the median time from the first cancer diagnosis to LS confirmation was 5 years (IQR: 2&#8211;15 years), with variability depending on the cancer type. Breast and ovarian cancers were the most common non-CRC/EC first malignancies, each accounting for 15% (15 cases) of the total. Urothelial/Kidney cancer followed at 11% (12 cases), while gastric cancer and thyroid cancer each represented 9% (9 cases). Pancreatic and brain cancers were observed in 8% (8 cases each), with smaller proportions reported for skin (5%), small bowel (5%), and sarcoma (4%). Other cancers, such as prostate, bladder, pulmonary, cholangiocarcinoma, testicular, and gallbladder cancers, collectively accounted for 1&#8211;2% of cases each. The proportion of cancers diagnosed before the confirmation of LS varied among cancer types. Ovarian cancer (13%, 8 cases), breast cancer (13%, 8 cases) and urothelial/kidney cancer (12%, 8 cases) were frequently identified prior to LS diagnosis. Thyroid cancer was detected before LS diagnosis in 11% (7 cases), followed by brain cancer and skin cancer, each at 8% (5 cases). Other cancers, including pancreatic (3%, 2 cases) and small bowel (5%, 3 cases), were less commonly diagnosed before LS diagnosis. The median interval between cancer diagnosis and LS confirmation varied significantly by cancer type. Among the most frequent cancers, ovarian exhibited the longest median interval at 15 y (IQR: 7&#8211;24), followed by pancreatic cancer (14 y, IQR: 1&#8211;18). Breast and gastric cancers had median intervals of 5 y (IQR: 3&#8211;14 and 2&#8211;13, respectively), while shorter intervals were observed for urothelial/kidney (4 y, IQR: 1&#8211;8) and thyroid cancers (4 y, IQR: 3&#8211;13). Among the 63 patients presenting with a primary non-CRC/EC prior to a LS diagnosis, 46% (29 cases) were subsequently diagnosed with CRC or EC. Of these, 33% (21 cases) developed CRC, with a median interval of 10 years (IQR: 5&#8211;15) between the initial non-CRC/EC diagnosis and CRC diagnosis. EC accounted for 13% (8 cases) of subsequent malignancies, with a median interval of 6 y (IQR: 2&#8211;9). Overall, the combined median interval to CRC or EC diagnosis was 8 y (IQR: 7&#8211;10).<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Timing and Distribution of Non-CRC/EC malignancies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Cancer type</th><th colspan="1" rowspan="1">Presented as first cancer (n = 98)</th><th colspan="1" rowspan="1">Presented before LS diagnosis (n = 63)</th><th colspan="1" rowspan="1">Years before LS diagnosis (Median; [IQR])</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Urothelium/Kidney (N (%))</td><td align="char" colspan="1" rowspan="1">12 (11%)</td><td align="char" colspan="1" rowspan="1">8 (12%)</td><td colspan="1" rowspan="1">4 [1&#8211;8]</td></tr><tr><td colspan="1" rowspan="1">Breast (N (%))</td><td align="char" colspan="1" rowspan="1">15 (15%)</td><td align="char" colspan="1" rowspan="1">8 (13%)</td><td colspan="1" rowspan="1">5 [3&#8211;14]</td></tr><tr><td colspan="1" rowspan="1">Gastric (N (%))</td><td align="char" colspan="1" rowspan="1">9 (9%)</td><td align="char" colspan="1" rowspan="1">6 (9%)</td><td colspan="1" rowspan="1">5 [2&#8211;13]</td></tr><tr><td colspan="1" rowspan="1">Ovarian (N (%))</td><td align="char" colspan="1" rowspan="1">15 (15%)</td><td align="char" colspan="1" rowspan="1">8 (13%)</td><td colspan="1" rowspan="1">15 [7&#8211;24]</td></tr><tr><td colspan="1" rowspan="1">Skin<xref rid="tbl3fna" ref-type="table-fn">a</xref> (N (%))</td><td align="char" colspan="1" rowspan="1">5 (5%)</td><td align="char" colspan="1" rowspan="1">5 (8%)</td><td colspan="1" rowspan="1">2 [1&#8211;3]</td></tr><tr><td colspan="1" rowspan="1">Small Bowel<xref rid="tbl3fnb" ref-type="table-fn">b</xref> (N (%))</td><td align="char" colspan="1" rowspan="1">5 (5%)</td><td align="char" colspan="1" rowspan="1">3 (5%)</td><td colspan="1" rowspan="1">3 [1&#8211;18]</td></tr><tr><td colspan="1" rowspan="1">Pancreas (N (%))</td><td align="char" colspan="1" rowspan="1">8 (8%)</td><td align="char" colspan="1" rowspan="1">2 (3%)</td><td colspan="1" rowspan="1">14 [1&#8211;18]</td></tr><tr><td colspan="1" rowspan="1">Brain (N (%))</td><td align="char" colspan="1" rowspan="1">8 (8%)</td><td align="char" colspan="1" rowspan="1">5 (8%)</td><td colspan="1" rowspan="1">7 [1&#8211;22]</td></tr><tr><td colspan="1" rowspan="1">Thyroid (N (%))</td><td align="char" colspan="1" rowspan="1">9 (9%)</td><td align="char" colspan="1" rowspan="1">7 (11%)</td><td colspan="1" rowspan="1">4 [3&#8211;13]</td></tr><tr><td colspan="1" rowspan="1">Prostate (N (%))</td><td align="char" colspan="1" rowspan="1">1 (1%)</td><td align="char" colspan="1" rowspan="1">1 (2%)</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">Bladder (N (%))</td><td align="char" colspan="1" rowspan="1">2 (2%)</td><td align="char" colspan="1" rowspan="1">1 (2%)</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Pulmonary (N (%))</td><td align="char" colspan="1" rowspan="1">2 (2%)</td><td align="char" colspan="1" rowspan="1">2 (3%)</td><td colspan="1" rowspan="1">7 [3&#8211;11]</td></tr><tr><td colspan="1" rowspan="1">Sarcoma (N (%))</td><td align="char" colspan="1" rowspan="1">4 (4%)</td><td align="char" colspan="1" rowspan="1">4 (6%)</td><td colspan="1" rowspan="1">15 [2&#8211;21]</td></tr><tr><td colspan="1" rowspan="1">Cholangiocarcinoma (N (%))</td><td align="char" colspan="1" rowspan="1">1 (1%)</td><td align="char" colspan="1" rowspan="1">1 (2%)</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Testis (N (%))</td><td align="char" colspan="1" rowspan="1">2 (2%)</td><td align="char" colspan="1" rowspan="1">1 (2%)</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="1">Gallbladder (N (%))</td><td align="char" colspan="1" rowspan="1">1 (1%)</td><td align="char" colspan="1" rowspan="1">1 (2%)</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Total (N (%))</td><td align="char" colspan="1" rowspan="1"><bold>98 (100%)</bold></td><td align="char" colspan="1" rowspan="1"><bold>63 (100%)</bold></td><td colspan="1" rowspan="1"><bold>5 [2</bold>&#8211;<bold>15]</bold></td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Subsequent CRC/EC diagnoses (Patients without LS diagnosis, presenting with a primary non-CRC/EC)</th><th colspan="1" rowspan="1">Number of cases (n = 29)</th><th colspan="1" rowspan="1">Years before CRC/EC diagnosis (Median; [IQR])</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Total patients presenting with a primary non-CRC/EC before LS diagnosis</td><td align="char" colspan="1" rowspan="1">63 (100%)</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">CRC (N (%))</td><td align="char" colspan="1" rowspan="1">21 (33%)</td><td colspan="1" rowspan="1">10 [5&#8211;15]</td></tr><tr><td colspan="1" rowspan="1">EC (N (%))</td><td align="char" colspan="1" rowspan="1">8 (13%)</td><td colspan="1" rowspan="1">6 [2&#8211;9]</td></tr><tr><td colspan="1" rowspan="1">Total (N (%))</td><td align="char" colspan="1" rowspan="1"><bold>29 (46%)</bold></td><td colspan="1" rowspan="1"><bold>8 [7</bold>&#8211;<bold>10]</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: LS: Lynch syndrome; CRC: colorectal cancer; EC: endometrial cancer; non-CRC/EC: non-colorectal/endometrial cancers; IQR: interquartile range.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0040">All sebaceous neoplasms.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0045">Includes adenocarcinoma of the duodenum, jejunum, and ileum.</p></fn></table-wrap-foot></table-wrap><fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Distribution of Non-CRC/EC</bold><bold>s</bold>. Pie chart illustrating the distribution of non-colorectal/endometrial cancers (n = 228) diagnosed in the LS cohort. Abbreviations: LS, Lynch syndrome; CRC, colorectal cancer; EC, endometrial cancer; non-CRC/EC, non-colorectal/endometrial cancers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0100">This study provides a comprehensive insight into the spectrum of non-CRC/ECs in patients with LS, particularly when these cancers represent the first manifestation of the syndrome. Currently, non-CRC/ECs are excluded from UTS, resulting in a significant proportion of LS-associated neoplasms remaining undetected. The study is retrospective and reports the tumors' incidence in the patients with LS followed at our Center, but the IHC assay for the MMR proteins is not available on the non-CRC/ECs. Therefore, the attribution of these tumors to germline MMR deficiency is conceivable, but it is not proven. With this limitation, our findings reveal that non-CRC/ECs accounted for 40% of all tumor type, with 17% of cases presenting as the initial malignancy. Among these, urothelial/kidney carcinoma was the most common non-CRC/EC, while ovarian and breast cancer were the most frequent non-CRC/ECs presented as initial tumors. These results align with previous research by Pande M. et al., who reported that 28% of patients with LS and cancer initially presented with non-CRC/ECs, predominantly skin, urothelial/kidney and ovarian cancers.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> In our cohort, non-CRC/ECs were more prevalent in <italic toggle="yes">MSH2</italic> mutation carriers, consistent with prior reports.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Interestingly, a significant proportion of these tumors are not included among the malignancy considered for the clinical diagnosis of LS.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Latham A. et al. identified microsatellite instability in over 50 different cancers and confirmed LS in patients with breast, thyroid, melanoma, and mesothelioma, further illustrating the syndrome's extensive tumor spectrum.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Notably, in our cohort, breast and thyroid cancer accounted for 5% and 3% of non-CRC/ECs, respectively, and were diagnosed at median ages approximately 10 years earlier than in the general population (55 and 43 years, respectively).<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> Although the debate on the attribution of breast and thyroid carcinomas to the spectrum of LS-related tumors is still open, these findings support the hypothesis that these neoplasms may be, even rarely, related to MMR deficiency.</p><p id="p0105">Moreover, 64% (63 cases) of the first non-CRC/ECs (98 cases) were diagnosed prior to LS confirmation, and 46% (29 cases) of these patients subsequently developed CRC and/or EC, tumors for which there are shared surveillance protocols for early detection. While the implementation of UTS for non-CRC/ECs in LS remains controversial due to concerns about cost, feasibility and test sensitivity, the potential benefits of early diagnosis of the syndrome should not be underestimated.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> The early identification of LS from non-CRC/ECs may allow cascading genetic testing and preventive strategies in at-risk relatives, further increasing the long-term cost-effectiveness of a broader screening approach.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> In addition, with the increasing availability of targeted therapies, such as immunotherapy for MSI-H tumors, integration of non-CRC/EC screening into LS management may optimize treatment decisions and resource allocation.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> A comparison of our findings with those from the Prospective Lynch Syndrome Database (PLSD) and the updated National Comprehensive Cancer Network (NCCN) guidelines (version 3.2024) is presented in <xref rid="tbl4" ref-type="table">Table 4</xref>.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> The effectiveness of surveillance for non-CRC LS-associated tumors in detecting these malignancies at an earlier stage&#8211;and thereby improving overall survival and quality of life&#8211;remains a topic of ongoing debate. In this context, a recent and insightful review by Abu-Freha and colleagues highlighted the differences between guidelines issued by leading scientific societies involved in the management of LS.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> The results of our study contribute to this ongoing discussion, although they are not intended to be definitive. Below, we discuss our findings in relation to the most common non-CRC/ECs, focusing on the potential role of UTS and the management strategies recommended by the most prominent guidelines.<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Comparison between our data, PLSD<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref>, and NCCN guidelines.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Non-CRC/EC cancer type</th><th colspan="1" rowspan="1">MLH1 (n = 167)</th><th colspan="1" rowspan="1">PLSD<break/>MLH1<xref rid="tbl4fna" ref-type="table-fn">a</xref></th><th colspan="1" rowspan="1">MSH2 (n = 273)</th><th colspan="1" rowspan="1">PLSD<break/>MSH2<xref rid="tbl4fna" ref-type="table-fn">a</xref></th><th colspan="1" rowspan="1">MSH6 (n = 72)</th><th colspan="1" rowspan="1">PLSD<break/>MSH6<xref rid="tbl4fna" ref-type="table-fn">a</xref></th><th colspan="1" rowspan="1">PMS2 (n = 47)</th><th colspan="1" rowspan="1">PLSD<break/>PMS2<xref rid="tbl4fna" ref-type="table-fn">a</xref></th><th colspan="1" rowspan="1">EPCAM (n = 11)</th><th colspan="1" rowspan="1">PLSD<break/>EPCAM</th><th colspan="1" rowspan="1">NCCN 3.2024<break/>Surveillance guidelines</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Urothelium/Kidney (N (%))</td><td colspan="1" rowspan="1">4 (2%) (2 M, 2 F)</td><td colspan="1" rowspan="1">2.5% [1.3&#8211;5.1] (M)<break/>1.7% [0.8&#8211;3.8] (F)</td><td colspan="1" rowspan="1">35 (13%) (15 M, 20 F)</td><td colspan="1" rowspan="1">11.5% [8.2&#8211;16.0] (M)<break/>9.7% [6.9&#8211;13.5] (F)</td><td colspan="1" rowspan="1">2 (3%) (2 F)</td><td colspan="1" rowspan="1">1.4% [0.3&#8211;5.4] (M)<break/>3.2% [1.3&#8211;7.4] (F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0% [NA] (M)<break/>0% [NA] (F)</td><td colspan="1" rowspan="1">3 (27%) (1 M, 1 F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Considered screening for individuals with a family history of urothelial cancer; annual urinalysis starting at age 30&#8211;35 <italic toggle="yes">(MLH1, MSH2, MSH6, PMS2)</italic></td></tr><tr><td colspan="1" rowspan="1">Bladder (N (%))</td><td colspan="1" rowspan="1">1 (1%) (1 M)</td><td colspan="1" rowspan="1">3.3% [1.8&#8211;6.1] (M)<break/>1.3% [0.6&#8211;3.2] (F)</td><td colspan="1" rowspan="1">6 (2%)<break/>(2 M, 4 F)</td><td colspan="1" rowspan="1">5.9% [3.7&#8211;9.4] (M)<break/>4.7% [2.8&#8211;7.7] (F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">3.0% [1.1&#8211;7.9] (M)<break/>1.8% [0.6&#8211;5.6] (F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0% [NA] (M)<break/>0% [NA] (F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Considered screening for individuals with a family history of urothelial cancer; annual urinalysis starting at age 30&#8211;35 <italic toggle="yes">(MLH1, MSH2, MSH6, PMS2)</italic></td></tr><tr><td colspan="1" rowspan="1">Breast (N (%))</td><td colspan="1" rowspan="1">8 (9% in the female population) (8 F)</td><td colspan="1" rowspan="1">12.3 [8.6&#8211;17.9]</td><td colspan="1" rowspan="1">11 (7% in the female population)) (11 F)</td><td colspan="1" rowspan="1">14.6 [10.3&#8211;21.1]</td><td colspan="1" rowspan="1">2 (4% in the female population)) (2 F)</td><td colspan="1" rowspan="1">13.7 [7.4&#8211;33.8]</td><td colspan="1" rowspan="1">5 (14% in the female population)) (5 F)</td><td colspan="1" rowspan="1">15.2 [5.9&#8211;51.9]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Current evidences do not support screening beyond general population recommendation <italic toggle="yes">(MLH1, MSH2, MSH6, PMS2)</italic></td></tr><tr><td colspan="1" rowspan="1">Gastric (N (%))</td><td colspan="1" rowspan="1">5 (3%) (3 M, 2 F)</td><td colspan="1" rowspan="1">2.8% [1.5&#8211;5.2] (M)<break/>2.0% [1.0&#8211;4.2] (F)</td><td colspan="1" rowspan="1">13 (5%) (9 M, 4 F)</td><td colspan="1" rowspan="1">4.3% [2.5&#8211;7.6] (M)<break/>2.6% [1.4&#8211;5.0] (F)</td><td colspan="1" rowspan="1">2 (3%) (1 M, 1 F)</td><td colspan="1" rowspan="1">0.7% [0.1&#8211;4.9] (M)<break/>0.7% [0.1&#8211;4.7] (F)</td><td colspan="1" rowspan="1">1 (2%) (1 F)</td><td colspan="1" rowspan="1">2.7% [0.4&#8211;17.5] (M)<break/>0% [NA] (F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Upper endoscopy starting at age 30&#8211;40 y and repeat every 2&#8211;4 y <italic toggle="yes">(MLH1, MSH2, MSH6, PMS2)</italic></td></tr><tr><td colspan="1" rowspan="1">Ovarian (N (%))</td><td colspan="1" rowspan="1">5 (6% in the female population)) (5 F)</td><td colspan="1" rowspan="1">8% [5.3&#8211;12.0]</td><td colspan="1" rowspan="1">15 (9% in the female population)) (15 F)</td><td colspan="1" rowspan="1">10.6% [7.2&#8211;15.6]</td><td colspan="1" rowspan="1">1 (2% in the female population)) (1 F)</td><td colspan="1" rowspan="1">0.7% [0.1&#8211;4.7]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0% [NA]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Bilateral salpingo-oophorectomy recommended <italic toggle="yes">(MLH1, MSH2, MSH6).</italic> Insufficient evidence for <italic toggle="yes">PMS2.</italic></td></tr><tr><td colspan="1" rowspan="1">Skin (N (%))</td><td colspan="1" rowspan="1">5 (3%) (1 M, 4 F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">8 (3%) (4 M, 4 F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">1 (1%) (1 F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">3 (6%) (1 M, 2 F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Consider skin exams every 1&#8211;2 years with a provider experienced in LS-associated skin manifestations; start age individualized <italic toggle="yes">(MLH1, MSH2, MSH6, PMS2)</italic></td></tr><tr><td colspan="1" rowspan="1">Small Bowel (N (%))</td><td colspan="1" rowspan="1">5 (3%) (1 M, 4 F)</td><td colspan="1" rowspan="1">4.4% [2.6&#8211;7.2] (M)<break/>2.5% [1.3&#8211;4.6] (F)</td><td colspan="1" rowspan="1">10 (4%) (5 M, 5 F)</td><td colspan="1" rowspan="1">4.5% [2.6&#8211;7.6] (M)<break/>3.2% [1.8&#8211;5.6] (F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.7% [0.1&#8211;4.8] (M)<break/>0.6% [0.1&#8211;4.0] (F)</td><td colspan="1" rowspan="1">1 (2%) (1 F)</td><td colspan="1" rowspan="1">3.3% [0.5&#8211;21.3] (M)<break/>2.1% [0.3&#8211;14.0] (F)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Upper endoscopy starting at age 30&#8211;40 y and repeat every 2&#8211;4 y <italic toggle="yes">(MLH1, MSH2, MSH6, PMS2)</italic></td></tr><tr><td colspan="1" rowspan="1">Pancreas (N (%))</td><td colspan="1" rowspan="1">8 (5%) (5 M, 3 F)</td><td colspan="1" rowspan="1">1.1% [0.4&#8211;2.9] (M)<break/>1.9% [0.9&#8211;4.0] (F)</td><td colspan="1" rowspan="1">5 (2%) (5 F)</td><td colspan="1" rowspan="1">1.4% [0.5&#8211;3.7] (M)<break/>1.2% [0.5&#8211;3.3] (F)</td><td colspan="1" rowspan="1">3 (5%) (2 M, 1 F)</td><td colspan="1" rowspan="1">0% [NA]<break/>0.7% [0.1&#8211;4.8]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0% [NA]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Considered surveillance for individuals with a family history of pancreatic cancer; starting at age 50 or 10 y before the earliest family diagnosis <italic toggle="yes">(MLH1, MSH2, MSH6)</italic> Insufficient evidence for <italic toggle="yes">PMS2</italic></td></tr><tr><td colspan="1" rowspan="1">Prostate (N (%))</td><td colspan="1" rowspan="1">1 (1% in the male population) (1 M)</td><td colspan="1" rowspan="1">5.3% [3.2&#8211;8.7]</td><td colspan="1" rowspan="1">7 (6% in the male population) (7 M)</td><td colspan="1" rowspan="1">10.6% [7.5&#8211;15.0]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">3.0% [1.1&#8211;7.7]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">3.3% [0.5&#8211;21.5]</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">PSA analysis starting at age 40 repeat annually <italic toggle="yes">(MLH1, MSH2, MSH6, PMS2)</italic></td></tr><tr><td colspan="1" rowspan="1">Sarcoma (N (%))</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.2%<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">6 (2%) (6 M)</td><td colspan="1" rowspan="1">0.2%<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.2%<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.2%<xref rid="tbl4fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">No data available <italic toggle="yes">(all GPVs)</italic></td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: LS: Lynch syndrome; CRC: colorectal cancer; EC: endometrial cancer; GPV: germline pathogenic variant; M: male; F: female; NA: not available; NCCN: National Comprehensive Cancer Network.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fna"><label>a</label><p id="ntpara0050">Cumulative incidence at 65 years [95% confidence interval].</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnb"><label>b</label><p id="ntpara0055">Cumulative incidence all mutation groups (14 cases in 6350 carriers).</p></fn></table-wrap-foot></table-wrap></p><p id="p0110">Urothelial/kidney cancers are a well-recognized extracolonic malignancy in LS, with risks 14-fold higher than in the general population and 75-fold higher in <italic toggle="yes">MSH2</italic> mutation carriers.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> In our study, urothelial/kidney cancer was the most frequently observed non-CRC/EC, predominantly affecting the <italic toggle="yes">MSH2</italic> group (13%). These findings align with data from the Prospective Lynch Syndrome Database (PLSD), which reported a cumulative incidence of 11.5% [8.2&#8211;16.0] by age 65 for <italic toggle="yes">MSH2</italic> mutation carriers.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Notably, 11% of cases in our cohort were identified as the initial manifestation of LS, with a median interval of 4 years (IQR: 1&#8211;8) from diagnosis to LS confirmation. Furthermore Elze et al. reported a high frequency of MSI-H in ureter (72%) and renal pelvis (92%) in LS cancers.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> Based on these findings, the integration of urothelial/kidney cancer into UTS protocols for LS should be strongly considered. Current guidelines give controversial suggestions for the surveillance of urothelium in patients with LS,<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> even if the European Association of Urology advises IHC testing of urothelial tumor specimens, followed by confirmatory genetic testing for LS, in all patients under 65 years of age or those with a personal or family history of LS-associated cancers.<xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref> Our results support the opportunity to screen at least <italic toggle="yes">MSH2</italic> mutation carriers for urothelial tumors. Bladder cancer has been observed in patients with LS, with an estimated lifetime risk of 5.9% [3.7&#8211;9.4] for <italic toggle="yes">MSH2</italic> mutation carriers.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> In our cohort, bladder cancer accounts for 1% of all non-CRC/ECs and occurs predominantly in <italic toggle="yes">MSH2</italic> carriers. These findings are consistent with previous studies estimating a cumulative incidence of 4.4&#8211;12.8% for bladder cancer by the age of 80 years, compared to 2.3% in the general population.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> However, these data should be interpreted with caution, either because bladder cancer is related to environmental and behavioral diffuse risks factors (e.g. tobacco use), either because some studies suggest that the higher incidence of bladder cancer in patients with LS may be due in part to secondary seeding from upper tract urothelial cancers rather than representing an independent primary neoplasm.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> While the direct relationship between LS and bladder cancer remains under investigation, the available evidence supports its inclusion in the spectrum of LS-associated tumors, particularly in <italic toggle="yes">MSH2</italic> mutation carriers.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Nevertheless, routine UTS for LS in all bladder cancer cases remains controversial. Although NCCN guidelines recommend considering bladder cancer screening in individuals with a family history of urothelial cancer and in those carrying pathogenic MSH2 variants, the relatively low prevalence (53%) of MSI-H in bladder cancer in patients with LS raises concerns about the cost-effectiveness and clinical utility of routine IHC or MSI testing in all bladder cancer cases.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></p><p id="p0115">Breast and prostate cancer, although less frequently associated with LS, remains a significant consideration. Recent studies propose that breast cancer may fall within the LS tumor spectrum; however, the evidence remains controversial.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Several large-scale studies, including that by Couch F et al., found no significant association, arguing against routine breast cancer surveillance in patients with LS.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> In our cohort, breast cancer accounted for 5% of non-CRC/ECs, with the highest prevalence observed in <italic toggle="yes">PMS2</italic> (14%) and <italic toggle="yes">MLH1</italic> (9%) female carriers of pathogenic variants. Among those who presented with breast cancer as the first malignancy, 53% were diagnosed prior to LS confirmation, with a median interval of 5 years (IQR: 3&#8211;14). Supporting of a possible link between breast cancer and LS, Elze et al. reported that while patients with LS do not have an overall increased risk of breast cancer compared to the general population, they do show a higher frequency of medullary-type breast carcinomas, which were almost always uniformly MSI-H.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> Despite these observations, the SIR in our cohort was 1.63 (95% CI: 0.98&#8211;2.28). Our data are therefore consistent with current NCCN guidelines, which do not recommend additional breast cancer surveillance beyond that offered to the general population.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Prostate cancer, though infrequent in our cohort (3% in the male population), was predominantly observed in <italic toggle="yes">MSH2</italic> mutation carriers, aligning with data from the PLSD and the IMPACT study.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> The low incidence of prostate cancer in our series can be explained by the underreporting of this tumor and by the youngest median age of the patients included in our study (50 years), if compared to the median age at diagnosis of prostate cancer in the general population (65 years).<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Evidence to support its inclusion in the LS tumor spectrum comes from a 2014 meta-analysis of 23 studies, which found that 74% of prostate cancers in patients with LS were MMR-deficient, with a relative risk of 3.67 in mutation carriers, particularly those with <italic toggle="yes">MSH2</italic> mutations.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> This association was further supported by Haraldsdottir et al., who reported a fivefold increase in prostate cancer incidence over a 10-year period in male individuals with LS,<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> and by data from the Danish LS cohort, which identified MMR deficiency in 69% of prostate cancer cases.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> Although our data, together with the observed prevalence in the general population (SIR 1.16; 95% CI: 0.43&#8211;2.52), are not sufficient to support routine UTS for prostate cancer<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref>(43).</p><p id="p0120">Gastric cancer is a recognized malignancy in LS, particularly in <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> mutation carriers.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> Studies report a lifetime risk of 4&#8211;5% for these groups.<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> In our cohort, gastric cancer accounted for 4% of non-CRC/ECs, with the highest prevalence in <italic toggle="yes">MSH2</italic> carriers (5%). Notably, 28% of cases were diagnosed before LS confirmation, with a median interval of 5 years (IQR: 2&#8211;13), and a SIR of 4.68 (95% CI: 2.90&#8211;7.16). Kumar and Coll reviewed the wide variability in gastric cancer surveillance proposed by the available guidelines on the LS management and collected studies in support of upper GI screening that would allow detection of precancerous lesions and malignancies at an earlier stage, if compared to symptoms-based diagnosis.<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref></p><p id="p0125">In addition, emerging data regarding the favorable prognostic significance and potential negative predictive role of microsatellite instability for neoadjuvant and adjuvant chemotherapy in resectable gastric cancer are reshaping the management of these patients.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> In addition, results from recent trials in both resectable and advanced gastric cancer have demonstrated the promising role of immunotherapy.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> These findings underscore the need to determine microsatellite status to tailor therapeutic strategies for these patients. In conclusion, considering the therapeutic and genetic implications, the integration of gastric cancer into UTS protocols for LS should be considered. However, current surveillance guidelines remain controversial. NCCN guidelines recommend biennial esophagogastroduodenoscopy starting at age 30&#8211;40, while others argue that evidence supporting gastric cancer surveillance are insufficient.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref></p><p id="p0130">In LS the cumulative risk of ovarian cancer at age 65 years is between 0.7% and 10%.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> In our cohort, ovarian cancer was diagnosed in 6% of the female patients with the highest prevalence in <italic toggle="yes">MSH2</italic> female carriers (9%). Notably, ovarian cancer exhibited the youngest median age of diagnosis among non-CRC/ECs (41 years) and was a frequent initial malignancy, accounting for 15% of first cancers. The SIR was 3.80 (95% CI: 2.32&#8211;5.87). It is well established that LS-associated ovarian tumors are predominantly of clear cell or endometrioid histology.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> In addition, MSI have been shown to predominantly affect ovarian tumors in younger women.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> Given these findings and the increasing importance of MSI testing in the management of recurrent or therapy-resistant ovarian cancer, expansion of UTS to include these malignancies should be considered, particularly in younger patients or those with specific histological subtypes.<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> Screening for gynecological cancers in LS has not proven effective in detecting pre-malignant lesions.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> Current guidelines recommend prophylactic hysterectomy and bilateral salpingo-oophorectomy for women who have completed childbearing, while annual gynecological evaluations with transvaginal ultrasound are advised for those who have not yet opted for prophylactic surgery.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></p><p id="p0135">Skin cancers, particularly sebaceous neoplasm, are often associated with Muir-Torre Syndrome<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> and <italic toggle="yes">MSH2</italic> carriers.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> In our cohort skin cancers accounted for 3% of non-CRC/ECs, 29% (5 cases) of which were melanomas. While sebaceous skin lesions and, in some reports, squamous and basal cell carcinomas are relatively common in patients with LS, melanoma has not been associated with the syndrome, a finding confirmed by the SIR of 0.51 (95% CI: 0.10&#8211;1.48).<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> Notably, in our series, all skin cancers occurred prior to LS confirmation, suggesting the possibility to expanding UTS, particularly in those patients with a personal or family history of sebaceous neoplasms.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> Routine skin surveillance is not universally recommended for LS patients, but dermatological evaluations every 1&#8211;2 years should be considered.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref></p><p id="p0140">Pancreatic cancer is an increasingly recognized extracolonic malignancy in LS, with <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> mutation carriers having a 3&#8211;5% lifetime risk.<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref><sup>,</sup><xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> In our cohort, it constituted 3% of all non-CRC/ECs, with a slightly higher prevalence observed in <italic toggle="yes">MLH1</italic> carriers (5%). Notably, 50% of cases were the first malignancy, and 12% were diagnosed before LS confirmation, with the longest intervals among LS-associated malignancies (14 years). In addition, although MSI-H pancreatic cancer is rare in general population (approximately 1% of pancreatic ductal adenocarcinoma), emerging evidence suggests that immunotherapy may be effective in these patients.<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref> These findings, together with a SIR of 3.09 (95% CI: 1.69&#8211;5.18), seems to support the inclusion of pancreatic cancer into UTS, particularly for patients presenting with cancer at a younger age. Current guidelines recommend considering annual pancreatic surveillance for individuals with a family history of pancreatic cancer beginning at age 50 or 10 years before the earliest family member for <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic> and <italic toggle="yes">MSH6</italic> mutation carriers.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib80" ref-type="bibr"><sup>80</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> Even if, pros and cons of pancreatic surveillance are still matter of debate, it is clear that it needs high skilled health professionals and multidisciplinary discussion, and, hopefully, the inclusion of patients in dedicated registries<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref></p><p id="p0145">Duodenal and jejunal cancers are established extracolonic malignancies in LS, with a lifetime risk of 4.5% [2.6&#8211;7.2] for <italic toggle="yes">MLH1</italic> and 4.4% [2.6&#8211;7.6] for <italic toggle="yes">MSH2</italic> mutation carriers.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> In our cohort, small bowel cancers represented 3% of non-CRC/ECs, with the majority (81%, 13 cases) being duodenal or jejunal cancers. The 31% of small bowel cancers were identified as the first malignancy and 60% of them were diagnosed before LS confirmation. The median interval to LS confirmation was 3 years (IQR: 1&#8211;18). Given the elevated risk of small bowel disease and the frequent role as an early sentinel malignancy, expanding UTS protocols to include small bowel cancer may enable earlier LS diagnosis. Moreover, the immunotherapy agnostic indication for the treatment of advanced MSI-H tumors included small bowel, biliary and gastric cancer highlights the paramount importance to integrate the microsatellite status in the diagnosis of these tumors.</p><p id="p0150">Other malignancies, including sarcoma, pulmonary, testicular, and gallbladder cancers, collectively represented 1&#8211;2% of non-CRC/ECs in our LS cohort. Sarcomas were most frequently observed in <italic toggle="yes">MSH2</italic> mutation carriers (2%), with a median interval of 15 years (IQR: 2&#8211;21) from diagnosis to LS confirmation. Similar results were reported by Nilbert et al. in the National Danish Registry, which identified sarcomas as 1% of extracolonic malignancies, with <italic toggle="yes">MSH2</italic> (50%), <italic toggle="yes">MLH1</italic> (29%), and <italic toggle="yes">MSH6</italic> (21%) being the most commonly involved mutations.<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> Similar reports were also derived by the PLSD.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Although these cancers are infrequent in LS, their occurrence underscores the various cancer spectrum associated with the syndrome. Currently, there is insufficient evidence to recommend UTS in these cases.</p><p id="p0155">The clinical utility and cost-effectiveness of UTS for LS in CRC and EC are well established, with multiple economic models reporting favorable incremental cost-effectiveness ratios (ICERs) ranging from $13,000 to $25,000 per quality-adjusted life year (QALY) gained.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib85" ref-type="bibr">85</xref>, <xref rid="bib86" ref-type="bibr">86</xref>, <xref rid="bib87" ref-type="bibr">87</xref>, <xref rid="bib88" ref-type="bibr">88</xref> These findings, when considered in conjunction with recently published data, indicate that a similar logic may be applicable to extracolonic LS-associated tumors. In pancreatic cancer, while the prevalence of dMMR is low (1&#8211;2%), actionable germline mutations have been identified even in patients without family history.<xref rid="bib89" ref-type="bibr">89</xref>, <xref rid="bib90" ref-type="bibr">90</xref>, <xref rid="bib91" ref-type="bibr">91</xref> Krepline et al. developed a cost-effectiveness model comparing universal versus selective germline testing for pancreatic ductal adenocarcinoma PDAC, concluding that selective testing based on clinical criteria (e.g. age and family history) is currently more economically sustainable.<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref><sup>,</sup><xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> However, as sequencing costs decline and immunotherapy indications expand, the feasibility of universal testing may improve. Data on small bowel adenocarcinoma and gastric cancer remain limited. Nevertheless, S&#225;nchez et al. reported that over 20% of small bowel tumors exhibit MMR deficiency, with more than half attributable to LS, supporting the rationale for universal MMR testing in this context.<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> Moreover, the KEYNOTE-158 trial demonstrated pembrolizumab efficacy in advanced MMR-deficient SBA, underscoring the therapeutic relevance of screening.<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> In gastric cancer, LS-associated tumors are typically intestinal-type and diagnosed at younger ages.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> Reflecting this evolving understanding, the 2025 NCCN guidelines now recommend MMR or MSI testing for all newly diagnosed gastric adenocarcinomas, given the potential for guiding immunotherapy eligibility.<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> In ovarian cancer, LS accounts for 10&#8211;15% of hereditary cases, particularly in early-onset, non-serous histologies.<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref> While BRCA1/2 testing remains the cornerstone of germline evaluation in high-grade serous ovarian carcinoma, panel-based approaches are increasingly utilized. In this context, the marginal cost of incorporating MMR testing is likely to become negligible. The integration of MMR analysis into broader germline panels could facilitate the detection of patients with LS that would otherwise be missed by BRCA-focused strategies, with important downstream implications for cascade testing and preventive interventions in at-risk relatives.<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref></p><p id="p0160">Similarly, LS accounts for an estimated 1&#8211;3% of upper tract urothelial carcinomas, and studies support routine IHC screening in patients under 60 years of age.<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> Sebaceous neoplasms, the hallmark of Muir&#8211;Torre syndrome, exhibit MMR deficiency in approximately 30% of cases, which reinforces the importance of universal MMR testing in this context.<xref rid="bib100" ref-type="bibr"><sup>100</sup></xref> All these data are supported by Kunnackal et al. that sustained the cost-effectiveness of performing UTS in all newly diagnosed ovarian cancers, upper tract urothelial carcinomas, and sebaceous neoplasms.<xref rid="bib101" ref-type="bibr"><sup>101</sup></xref></p><p id="p0165">This study analyzed a large cohort of patients with LS with detailed clinicopathological and genetic data, managed in a referral center for hereditary tumors in Northern Italy, providing robust insights into cancer risks and distribution by MMR subgroups. However, several limitations should be acknowledged. The retrospective design may introduce selection bias, and the small sample sizes in some subgroups, such as EPCAM, limit the generalizability of our findings. Additionally, variability in follow-up durations and incomplete data for rare cancers subtypes in our LS cohort (e.g. sarcoma, testicular, and gallbladder cancers) may underestimate their true prevalence and clinical significance. Moreover, another important limitation is the lack of IHC testing for MMR proteins in the extra-CRC/ECs. This limitation is shared by other retrospective and registry studies, that have studied the prevalence of different tumor types in patients with LS, published in highly cited journals, from which many of the current knowledge on tumors associated with LS comes.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> While we acknowledge that this prevents us from definitively demonstrating the association of these tumors with LS, it is important to point out that not all patients with extra-CRC/ECs were diagnosed and treated at our center. This limitation is mainly due to the size of the cohort and the temporal extension of our study, during which diagnostic practices have evolved. Additionally, studies by Latham et al. and Elze et al. have shown that a significant proportion of non-CRC/ECs in LS patients are microsatellite stable rather than MSI-H, particularly for certain tumor types of not unequivocally part of the LS spectrum (e.g. bladder cancer 53%, breast 36%, prostate 28%, and melanoma 0%).<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> These findings indicate that not all non-CRC/ECs in LS patients are necessarily MMR-deficient, suggesting that alternative oncogenic mechanisms may contribute to their development. Nevertheless, our clinicopathological and epidemiological analyses are in line with previous reports demonstrating the involvement of different tumor types besides colorectal and endometrial in LS.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Future studies incorporating systematic IHC and MSI testing in non-CRC/ECs will be essential to strengthen the evidence for their potential association with LS. Furthermore, we acknowledge the issue of multiple comparisons in our statistical analysis. Given the exploratory nature of this study, we did not apply a formal multiplicity adjustment. While this approach allows for a broader examination of potential associations, it also increases the risk of type I error inflation. Therefore, our findings should be interpreted with caution and further validation in independent prospectively collected datasets is warranted.</p><p id="p0170">Our understanding of LS has evolved significantly over time and continues to expand. The spectrum of extracolonic malignancies linked to the syndrome is broader than previously recognized and differs significantly from the original descriptions. In addition to the well-established malignancies, a growing number of additional cancers are emerging as candidates for inclusion in LS spectrum. At the same time, the role of extracolonic malignancies is evolving, as the index cancers may not be CRC or EC. Within the limitations of our retrospective design and the absence of IHC/MSI on non-CRC/ECs, our results suggest that UTS starting with CRC and EC only, although certainly a proven effective process, is insufficient to identify patients with LS in the general population.</p></sec><sec id="sec5"><title>Contributors</title><p id="p0175">Conceptualization: EDLU, FB; Data curation: FS, IM, SR, LDA, MCDG, GC, MF, MA, EDA, GS, FC, MM, MB, PP, SL, RI, VG, MVD, AM, DB, ADU, MI; formal analysis: SN, FC, MS; investigation: SN, EDLU; methodology: SN, FC; resources: GC, IM, SR, FS; supervision: FB, EDLU; writing&#8212;original draft: SN, FC; and writing&#8212;review &amp; editing: FB, EDLU, AM. All authors read and approved the final version of the manuscript. FB, EDLU, and FS accessed and verified the underlying data.</p></sec><sec id="sec6"><title>Data sharing statement</title><p id="p0180">Data from this study are not publicly available. De-identified participant data used in this study will be shared with researchers who submit a research proposal, upon approval of the proposal by our Ethics Committee. Additional related documents will not be made available.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of interests</title><p id="p0185">The authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Stoffel</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Everett</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Germline genetic features of young individuals with colorectal cancer</article-title><source>Gastroenterology</source><volume>154</volume><issue>4</issue><year>2018</year><fpage>897</fpage><lpage>905.e1</lpage><pub-id pub-id-type="pmid">29146522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2017.11.004</pub-id><pub-id pub-id-type="pmcid">PMC5847426</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Boland</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Yurgelun</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Boland</surname><given-names>C.R.</given-names></name></person-group><article-title>Recent progress in Lynch syndrome and other familial colorectal cancer syndromes</article-title><source>CA Cancer J Clin</source><volume>68</volume><issue>3</issue><year>2018</year><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">29485237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21448</pub-id><pub-id pub-id-type="pmcid">PMC5980692</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>P.</given-names></name></person-group><article-title>Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD)</article-title><source>Fam Cancer</source><volume>20</volume><issue>1</issue><year>2021</year><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">32507935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-020-00193-2</pub-id><pub-id pub-id-type="pmcid">PMC7870755</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T.T.</given-names></name><etal/></person-group><article-title>Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database</article-title><source>Genet Med</source><volume>22</volume><issue>1</issue><year>2020</year><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">31337882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-019-0596-9</pub-id><pub-id pub-id-type="pmcid">PMC7371626</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T.T.</given-names></name><etal/></person-group><article-title>Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database</article-title><source>eClinicalMedicine</source><volume>58</volume><year>2023</year><object-id pub-id-type="publisher-id">101909</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.101909</pub-id><pub-id pub-id-type="pmcid">PMC10166779</pub-id><pub-id pub-id-type="pmid">37181409</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>M&#248;ller</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective Lynch syndrome database and the international mismatch repair consortium</article-title><source>Hered Cancer Clin Pract</source><volume>20</volume><issue>1</issue><year>2022</year><fpage>36</fpage><pub-id pub-id-type="pmid">36182917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13053-022-00241-1</pub-id><pub-id pub-id-type="pmcid">PMC9526951</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Vasen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mecklin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>H.</given-names></name></person-group><article-title>New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC&#9734;</article-title><source>Gastroenterology</source><volume>116</volume><issue>6</issue><year>1999</year><fpage>1453</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">10348829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0016-5085(99)70510-x</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Umar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boland</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Terdiman</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability</article-title><source>J Natl Cancer Inst</source><volume>96</volume><issue>4</issue><year>2004</year><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">14970275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djh034</pub-id><pub-id pub-id-type="pmcid">PMC2933058</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Vindigni</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kaz</surname><given-names>A.M.</given-names></name></person-group><article-title>Universal screening of colorectal cancers for Lynch syndrome: challenges and opportunities</article-title><source>Dig Dis Sci</source><volume>61</volume><issue>4</issue><year>2016</year><fpage>969</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">26602911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-015-3964-6</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Adar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome</article-title><source>Cancer</source><volume>124</volume><issue>15</issue><year>2018</year><fpage>3145</fpage><lpage>3153</lpage><pub-id pub-id-type="pmid">29750335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.31534</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Tibiletti</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Carnevali</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cal&#242;</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Universal testing for MSI/MMR status in colorectal and endometrial cancers to identify Lynch syndrome cases: state of the art in Italy and consensus recommendations from the Italian Association for the Study of Familial Gastrointestinal Tumors (A.I.F.E.G.)</article-title><source>Eur J Cancer Prev</source><volume>31</volume><issue>1</issue><year>2022</year><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">33767077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CEJ.0000000000000677</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Grillo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Paudice</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pigozzi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>BRAF <sup>V600E</sup> immunohistochemistry can reliably substitute <italic toggle="yes">BRAF</italic> molecular testing in the Lynch syndrome screening algorithm in colorectal cancer</article-title><source>Histopathology</source><volume>84</volume><issue>5</issue><year>2024</year><fpage>877</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">38173291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/his.15133</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Giardiello</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Axilbund</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer</article-title><source>Gastroenterology</source><volume>147</volume><issue>2</issue><year>2014</year><fpage>502</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">25043945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.04.001</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Bl&#228;ker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morak</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Age-dependent performance of <italic toggle="yes">BRAF</italic> mutation testing in Lynch syndrome diagnostics</article-title><source>Int J Cancer</source><volume>147</volume><issue>10</issue><year>2020</year><fpage>2801</fpage><lpage>2810</lpage><pub-id pub-id-type="pmid">32875553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33273</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Yurgelun</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name></person-group><article-title>Recent advances in Lynch syndrome: diagnosis, treatment, and cancer prevention</article-title><source>Am Soc Clin Oncol Educ Book</source><volume>38</volume><year>2018</year><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">30231390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/EDBK_208341</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Lindor</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>M.A.</given-names></name></person-group><article-title>Risk of breast cancer in Lynch syndrome: a systematic review</article-title><source>Breast Cancer Res</source><volume>15</volume><issue>2</issue><year>2013</year><object-id pub-id-type="publisher-id">R27</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/bcr3405</pub-id><pub-id pub-id-type="pmcid">PMC3672741</pub-id><pub-id pub-id-type="pmid">23510156</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Provenzale</surname><given-names>D.</given-names></name><name name-style="western"><surname>Llor</surname><given-names>X.</given-names></name><etal/></person-group><article-title>NCCN guidelines insights: genetic/familial high-risk assessment: colorectal, version 2.2019</article-title><source>J Natl Compr Cancer Netw</source><volume>17</volume><issue>9</issue><year>2019</year><fpage>1032</fpage><lpage>1041</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2019.0044</pub-id><pub-id pub-id-type="pmid">31487681</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Latchford</surname><given-names>A.</given-names></name><name name-style="western"><surname>Negoi</surname><given-names>I.</given-names></name><etal/></person-group><article-title>European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender</article-title><source>Br J Surg</source><volume>108</volume><issue>5</issue><year>2021</year><fpage>484</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">34043773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bjs.11902</pub-id><pub-id pub-id-type="pmcid">PMC10364896</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Win</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dowty</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Prevalence and penetrance of major genes and polygenes for colorectal cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>26</volume><issue>3</issue><year>2017</year><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">27799157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-16-0693</pub-id><pub-id pub-id-type="pmcid">PMC5336409</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bale</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title><source>Genet Med</source><volume>17</volume><issue>5</issue><year>2015</year><fpage>405</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">25741868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmcid">PMC4544753</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Rivera-Mu&#241;oz</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Milko</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation</article-title><source>Hum Mutat</source><volume>39</volume><issue>11</issue><year>2018</year><fpage>1614</fpage><lpage>1622</lpage><pub-id pub-id-type="pmid">30311389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.23645</pub-id><pub-id pub-id-type="pmcid">PMC6225902</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R.Y.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>ClinGen pathogenicity calculator: a configurable system for assessing pathogenicity of genetic variants</article-title><source>Genome Med</source><volume>9</volume><issue>1</issue><year>2017</year><fpage>3</fpage><pub-id pub-id-type="pmid">28081714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-016-0391-z</pub-id><pub-id pub-id-type="pmcid">PMC5228115</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Kempers</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kuiper</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ockeloen</surname><given-names>C.W.</given-names></name><etal/></person-group><article-title>Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study</article-title><source>Lancet Oncol</source><volume>12</volume><issue>1</issue><year>2011</year><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">21145788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(10)70265-5</pub-id><pub-id pub-id-type="pmcid">PMC3670774</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Ligtenberg</surname><given-names>M.J.L.</given-names></name><name name-style="western"><surname>Kuiper</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Geurts van Kessel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoogerbrugge</surname><given-names>N.</given-names></name></person-group><article-title>EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients</article-title><source>Fam Cancer</source><volume>12</volume><issue>2</issue><year>2013</year><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">23264089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-012-9591-x</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="other" id="sref25"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org" id="intref0020">http://varnomen.hgvs.org</ext-link></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="other" id="sref26"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicalgenome.org" id="intref0025">https://clinicalgenome.org</ext-link></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><volume>74</volume><issue>3</issue><year>2024</year><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="other" id="sref28"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://seer.cancer.gov/statistics/" id="intref0030">https://seer.cancer.gov/statistics/</ext-link></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Pande</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry</article-title><source>Fam Cancer</source><volume>11</volume><issue>3</issue><year>2012</year><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">22714864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-012-9534-6</pub-id><pub-id pub-id-type="pmcid">PMC3475767</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Bandipalliam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Syngal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kolodner</surname><given-names>R.D.</given-names></name></person-group><article-title>Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer</article-title><source>Gastroenterology</source><volume>126</volume><issue>3</issue><year>2004</year><fpage>936</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">14988860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2004.01.038</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>van der Post</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kiemeney</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Ligtenberg</surname><given-names>M.J.L.</given-names></name><etal/></person-group><article-title>Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers</article-title><source>J Med Genet</source><volume>47</volume><issue>7</issue><year>2010</year><fpage>464</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">20591884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.2010.076992</pub-id><pub-id pub-id-type="pmcid">PMC2991077</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Trujillo-Rojas</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ayala-Madrigal</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Guti&#233;rrez-Angulo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Mercado</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moreno-Ortiz</surname><given-names>J.M.</given-names></name></person-group><article-title>Diagnosis of patients with Lynch syndrome lacking the Amsterdam II or Bethesda criteria</article-title><source>Hered Cancer Clin Pract</source><volume>21</volume><issue>1</issue><year>2023</year><fpage>21</fpage><pub-id pub-id-type="pmid">37864171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13053-023-00266-0</pub-id><pub-id pub-id-type="pmcid">PMC10589993</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Latham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kemel</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer</article-title><source>J Clin Oncol</source><volume>37</volume><issue>4</issue><year>2019</year><fpage>286</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">30376427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.18.00283</pub-id><pub-id pub-id-type="pmcid">PMC6553803</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="other" id="sref34"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://seer.cancer.gov/statfacts/html/thyro.html" id="intref0035">https://seer.cancer.gov/statfacts/html/thyro.html</ext-link></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="other" id="sref35"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://seer.cancer.gov/statfacts/html/breast.html" id="intref0040">https://seer.cancer.gov/statfacts/html/breast.html</ext-link></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Di Marco</surname><given-names>M.</given-names></name><name name-style="western"><surname>D'Andrea</surname><given-names>E.</given-names></name><name name-style="western"><surname>Panic</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Which Lynch syndrome screening programs could be implemented in the &#8220;real world&#8221;? A systematic review of economic evaluations</article-title><source>Genet Med</source><volume>20</volume><issue>10</issue><year>2018</year><fpage>1131</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">29300371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2017.244</pub-id><pub-id pub-id-type="pmcid">PMC8660650</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Mvundura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grosse</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Palomaki</surname><given-names>G.E.</given-names></name></person-group><article-title>The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer</article-title><source>Genet Med</source><volume>12</volume><issue>2</issue><year>2010</year><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">20084010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GIM.0b013e3181cd666c</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Ladabaum</surname><given-names>U.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Terdiman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Strategies to identify the Lynch syndrome among patients with colorectal cancer</article-title><source>Ann Intern Med</source><volume>155</volume><issue>2</issue><year>2011</year><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">21768580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-155-2-201107190-00002</pub-id><pub-id pub-id-type="pmcid">PMC3793257</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Elze</surname><given-names>L.</given-names></name><name name-style="western"><surname>van der Post</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome</article-title><source>J Natl Cancer Inst</source><volume>115</volume><issue>7</issue><year>2023</year><fpage>853</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">37018159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djad063</pub-id><pub-id pub-id-type="pmcid">PMC10323896</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Hodan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Genetic/familial high-risk assessment: colorectal, endometrial, and gastric, version 3.2024, NCCN clinical practice guidelines in oncology</article-title><source>J Natl Compr Cancer Netw</source><volume>22</volume><issue>10</issue><year>2024</year><fpage>695</fpage><lpage>711</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2024.0061</pub-id><pub-id pub-id-type="pmid">39689429</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T.T.</given-names></name></person-group><article-title>Analysis in the prospective Lynch syndrome database identifies sarcoma as part of the Lynch syndrome tumor spectrum</article-title><source>Int J Cancer</source><volume>148</volume><issue>2</issue><year>2021</year><fpage>512</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">32783184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33214</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Freha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hozaeel</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weissmann</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Lynch syndrome: similarities and differences of recommendations in published guidelines</article-title><source>J Gastroenterol Hepatol</source><volume>40</volume><issue>3</issue><year>2025</year><fpage>564</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">39797698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.16881</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Lonati</surname><given-names>C.</given-names></name><name name-style="western"><surname>Necchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>G&#243;mez Rivas</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Upper tract urothelial carcinoma in the Lynch syndrome tumour spectrum: a comprehensive overview from the European association of urology - young academic urologists and the global society of rare genitourinary tumors</article-title><source>Eur Urol Oncol</source><volume>5</volume><issue>1</issue><year>2022</year><fpage>30</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">34896051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.euo.2021.11.001</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Mork</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hubosky</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Roupr&#234;t</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lynch syndrome: a primer for urologists and panel recommendations</article-title><source>J Urol</source><volume>194</volume><issue>1</issue><year>2015</year><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">25711197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.juro.2015.02.081</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Genetic/familial high-risk assessment: colorectal, version 1.2021 featured updates to the NCCN guidelines</article-title><source>J Natl Compr Canc Netw</source><volume>19</volume><issue>10</issue><year>2021</year><fpage>1122</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">34666312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/jnccn.2021.0048</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Stjepanovic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up&#8224;</article-title><source>Ann Oncol</source><volume>30</volume><issue>10</issue><year>2019</year><fpage>1558</fpage><lpage>1571</lpage><pub-id pub-id-type="pmid">31378807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz233</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Lonati</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simeone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Suardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Spiess</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Necchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moschini</surname><given-names>M.</given-names></name></person-group><article-title>Genitourinary manifestations of Lynch syndrome in the urological practice</article-title><source>Asian J Urol</source><volume>9</volume><issue>4</issue><year>2022</year><fpage>443</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">36381590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajur.2022.05.009</pub-id><pub-id pub-id-type="pmcid">PMC9643301</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Engel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Loeffler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Steinke</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Risks of less common cancers in proven mutation carriers with Lynch syndrome</article-title><source>J Clin Oncol</source><volume>30</volume><issue>35</issue><year>2012</year><fpage>4409</fpage><lpage>4415</lpage><pub-id pub-id-type="pmid">23091106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.43.2278</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Joost</surname><given-names>P.</given-names></name><name name-style="western"><surname>Therkildsen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M.</given-names></name><name name-style="western"><surname>J&#246;nsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nilbert</surname><given-names>M.</given-names></name></person-group><article-title>Urinary tract cancer in Lynch syndrome; increased risk in carriers of MSH2 mutations</article-title><source>Urology</source><volume>86</volume><issue>6</issue><year>2015</year><fpage>1212</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">26385421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urology.2015.08.018</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Matin</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Lawrentschuk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roupret</surname><given-names>M.</given-names></name></person-group><article-title>Systematic review: an update on the spectrum of urological malignancies in Lynch syndrome</article-title><source>Bladder Cancer</source><volume>4</volume><issue>3</issue><year>2018</year><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">30112437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/BLC-180180</pub-id><pub-id pub-id-type="pmcid">PMC6087433</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Couch</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Shimelis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Associations between cancer predisposition testing panel genes and breast cancer</article-title><source>JAMA Oncol</source><volume>3</volume><issue>9</issue><year>2017</year><fpage>1190</fpage><pub-id pub-id-type="pmid">28418444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2017.0424</pub-id><pub-id pub-id-type="pmcid">PMC5599323</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Bancroft</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Page</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Brook</surname><given-names>M.N.</given-names></name><etal/></person-group><article-title>A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study</article-title><source>Lancet Oncol</source><volume>22</volume><issue>11</issue><year>2021</year><fpage>1618</fpage><lpage>1631</lpage><pub-id pub-id-type="pmid">34678156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00522-2</pub-id><pub-id pub-id-type="pmcid">PMC8576477</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Win</surname><given-names>A.K.</given-names></name></person-group><article-title>Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>23</volume><issue>3</issue><year>2014</year><fpage>437</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">24425144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-13-1165</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Haraldsdottir</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Prostate cancer incidence in males with Lynch syndrome</article-title><source>Genet Med</source><volume>16</volume><issue>7</issue><year>2014</year><fpage>553</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">24434690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2013.193</pub-id><pub-id pub-id-type="pmcid">PMC4289599</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Valentin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Joost</surname><given-names>P.</given-names></name><name name-style="western"><surname>Therkildsen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rambech</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nilbert</surname><given-names>M.</given-names></name></person-group><article-title>Frequent mismatch-repair defects link prostate cancer to Lynch syndrome</article-title><source>BMC Urol</source><volume>16</volume><issue>1</issue><year>2016</year><fpage>15</fpage><pub-id pub-id-type="pmid">27013479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12894-016-0130-1</pub-id><pub-id pub-id-type="pmcid">PMC4806412</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Capelle</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Van Grieken</surname><given-names>N.C.T.</given-names></name><name name-style="western"><surname>Lingsma</surname><given-names>H.F.</given-names></name><etal/></person-group><article-title>Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands</article-title><source>Gastroenterology</source><volume>138</volume><issue>2</issue><year>2010</year><fpage>487</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">19900449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2009.10.051</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Caspers</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Eikenboom</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Lopez-Yurda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gastric and duodenal cancer in individuals with Lynch syndrome: a nationwide cohort study</article-title><source>eClinicalMedicine</source><volume>69</volume><year>2024</year><object-id pub-id-type="publisher-id">102494</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2024.102494</pub-id><pub-id pub-id-type="pmcid">PMC10884743</pub-id><pub-id pub-id-type="pmid">38404296</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Katona</surname><given-names>B.W.</given-names></name></person-group><article-title>Upper gastrointestinal cancer surveillance in Lynch syndrome</article-title><source>Cancers (Basel)</source><volume>14</volume><issue>4</issue><year>2022</year><fpage>1000</fpage><pub-id pub-id-type="pmid">35205747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14041000</pub-id><pub-id pub-id-type="pmcid">PMC8869779</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Lordick</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cascinu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><volume>33</volume><issue>10</issue><year>2022</year><fpage>1005</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">35914639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.07.004</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Raimondi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murgioni</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO</article-title><source>Ann Oncol</source><volume>36</volume><year>2025</year><fpage>285</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">39637944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2024.11.016</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Pietrantonio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Randon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Bartolomeo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials</article-title><source>ESMO Open</source><volume>6</volume><issue>1</issue><year>2021</year><object-id pub-id-type="publisher-id">100036</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.esmoop.2020.100036</pub-id><pub-id pub-id-type="pmcid">PMC7815473</pub-id><pub-id pub-id-type="pmid">33460964</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Syngal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brand</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Church</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Giardiello</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>R.W.</given-names></name></person-group><article-title>ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes</article-title><source>Am J Gastroenterol</source><volume>110</volume><issue>2</issue><year>2015</year><fpage>223</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">25645574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2014.435</pub-id><pub-id pub-id-type="pmcid">PMC4695986</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>van Leerdam</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>van Hooft</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline</article-title><source>Endoscopy</source><volume>51</volume><issue>11</issue><year>2019</year><fpage>1082</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">31597170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1016-4977</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Vierkoetter</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Ayabe</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>VanDrunen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>K.Y.</given-names></name></person-group><article-title>Lynch syndrome in patients with clear cell and endometrioid cancers of the ovary</article-title><source>Gynecol Oncol</source><volume>135</volume><issue>1</issue><year>2014</year><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">25093288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2014.07.100</pub-id><pub-id pub-id-type="pmcid">PMC4492474</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Mariappan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Putcha</surname><given-names>G.V.</given-names></name><etal/></person-group><article-title>Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger</article-title><source>Am J Surg Pathol</source><volume>32</volume><issue>7</issue><year>2008</year><fpage>1029</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">18469706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0b013e31816380c4</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berchuck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Backes</surname><given-names>F.J.</given-names></name><etal/></person-group><article-title>NCCN guidelines&#174; insights: Ovarian cancer/fallopian tube cancer/primary peritoneal cancer, version 3.2024</article-title><source>J Natl Compr Cancer Netw</source><volume>22</volume><issue>8</issue><year>2024</year><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2024.0052</pub-id><pub-id pub-id-type="pmid">39413835</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Mitric</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abrahamyan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Mismatch-repair deficiency, microsatellite instability, and Lynch syndrome in ovarian cancer: a systematic review and meta-analysis</article-title><source>Gynecol Oncol</source><volume>170</volume><year>2023</year><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">36682091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2022.12.008</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Young</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Macrae</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>C.</given-names></name></person-group><article-title>Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review</article-title><source>Int J Gynecol Cancer</source><volume>32</volume><issue>5</issue><year>2022</year><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">35437274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ijgc-2021-003132</pub-id><pub-id pub-id-type="pmcid">PMC9067008</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Chitoran</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bohiltea</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Rotaru</surname><given-names>V.</given-names></name><name name-style="western"><surname>Durdu</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Mitroiu</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Simion</surname><given-names>L.</given-names></name></person-group><article-title>Gynecological insights into Lynch syndrome&#8212;A comprehensive review of cancer screening and prevention</article-title><source>Medicina</source><volume>60</volume><issue>12</issue><year>2024</year><fpage>2013</fpage><pub-id pub-id-type="pmid">39768893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medicina60122013</pub-id><pub-id pub-id-type="pmcid">PMC11728026</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Kohn</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Muir-Torre syndrome</article-title><source>Dermatol Clin</source><volume>13</volume><issue>1</issue><year>1995</year><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">7712655</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Lynch</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Pester</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fusaro</surname><given-names>R.M.</given-names></name></person-group><article-title>The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome</article-title><source>Arch Intern Med</source><volume>141</volume><issue>5</issue><year>1981</year><fpage>607</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">7224741</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Goecke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schulmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Genotype-phenotype comparison of German <italic toggle="yes">MLH1</italic> and <italic toggle="yes">MSH2</italic> mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC consortium</article-title><source>J Clin Oncol</source><volume>24</volume><issue>26</issue><year>2006</year><fpage>4285</fpage><lpage>4292</lpage><pub-id pub-id-type="pmid">16908935</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.03.7333</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Sowter</surname><given-names>P.</given-names></name><name name-style="western"><surname>Santibanez-Koref</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Response to &#8216;cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours</article-title><source>Br J Dermatol</source><volume>186</volume><issue>5</issue><year>2022</year><fpage>913</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">35322414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.20970</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Ykema</surname><given-names>B.L.M.</given-names></name><name name-style="western"><surname>Adan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Crijns</surname><given-names>M.B.</given-names></name><etal/></person-group><article-title>Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndrome-associated tumours</article-title><source>Br J Dermatol</source><volume>185</volume><issue>2</issue><year>2021</year><fpage>462</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">33829484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.20139</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Aziz</surname><given-names>S.</given-names></name><name name-style="western"><surname>O'Sullivan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Heelan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>A.</given-names></name><name name-style="western"><surname>McVeigh</surname><given-names>T.P.</given-names></name></person-group><article-title>Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with Lynch syndrome: a systematic review</article-title><source>Fam Cancer</source><volume>22</volume><issue>2</issue><year>2023</year><fpage>167</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">36418753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-022-00319-8</pub-id><pub-id pub-id-type="pmcid">PMC10020322</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><collab>Muir&#8211;Torre syndrome</collab></person-group><article-title>Surgical management and cancer screening guidelines</article-title><source>J Am Acad Dermatol</source><volume>64</volume><issue>2</issue><year>2011</year><object-id pub-id-type="publisher-id">AB85</object-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Barrow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alduaij</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations</article-title><source>Clin Genet</source><volume>75</volume><issue>2</issue><year>2009</year><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">19215248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-0004.2008.01125.x</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Aarnio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mecklin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aaltonen</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Nystr&#246;m-Lahti</surname><given-names>M.</given-names></name><name name-style="western"><surname>J&#228;rvinen</surname><given-names>H.J.</given-names></name></person-group><article-title>Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (hnpcc) syndrome</article-title><source>Int J Cancer</source><volume>64</volume><issue>6</issue><year>1995</year><fpage>430</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">8550246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.2910640613</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Ta&#239;eb</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sayah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heinrich</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort</article-title><source>Eur J Cancer</source><volume>188</volume><year>2023</year><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">37229836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2023.04.012</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Suguitan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>A.</given-names></name></person-group><article-title>Identification of high-risk germline variants for the development of pancreatic cancer: common characteristics and potential guidance to screening guidelines</article-title><source>Pancreatology</source><volume>22</volume><issue>6</issue><year>2022</year><fpage>719</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">35798629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pan.2022.05.005</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Goggins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Overbeek</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Brand</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium</article-title><source>Gut</source><volume>69</volume><issue>1</issue><year>2020</year><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">31672839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2019-319352</pub-id><pub-id pub-id-type="pmcid">PMC7295005</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Archibugi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Casciani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carrara</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance in high-risk individuals</article-title><source>Fam Cancer</source><volume>23</volume><issue>3</issue><year>2024</year><fpage>373</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">38493228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-024-00366-3</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Bonadona</surname><given-names>V.</given-names></name></person-group><article-title>Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome</article-title><source>JAMA</source><volume>305</volume><issue>22</issue><year>2011</year><fpage>2304</fpage><pub-id pub-id-type="pmid">21642682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2011.743</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Nilbert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Therkildsen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nissen</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#197;kerman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>I.</given-names></name></person-group><article-title>Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum</article-title><source>Fam Cancer</source><volume>8</volume><issue>3</issue><year>2009</year><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">19130300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-008-9230-8</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Killen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caruana</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome</article-title><source>Med J Aust</source><volume>212</volume><issue>2</issue><year>2020</year><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">31595523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5694/mja2.50356</pub-id><pub-id pub-id-type="pmcid">PMC7027559</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Snowsill</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>N.A.J.</given-names></name><name name-style="western"><surname>Crosbie</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Frayling</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>C.J.</given-names></name></person-group><article-title>Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting</article-title><source>PLoS One</source><volume>14</volume><issue>8</issue><year>2019</year><object-id pub-id-type="publisher-id">e0221419</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0221419</pub-id><pub-id pub-id-type="pmcid">PMC6716649</pub-id><pub-id pub-id-type="pmid">31469860</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Dinh</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Rosner</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Atwood</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population</article-title><source>Cancer Prev Res</source><volume>4</volume><issue>1</issue><year>2011</year><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1940-6207.CAPR-10-0262</pub-id><pub-id pub-id-type="pmcid">PMC3793254</pub-id><pub-id pub-id-type="pmid">21088223</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Leenen</surname><given-names>C.H.M.</given-names></name><name name-style="western"><surname>Goverde</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Bekker-Grob</surname><given-names>E.W.</given-names></name><etal/></person-group><article-title>Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age</article-title><source>Genet Med</source><volume>18</volume><issue>10</issue><year>2016</year><fpage>966</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">26938782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.206</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Luchini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brosens</surname><given-names>L.A.A.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>L.D.</given-names></name><etal/></person-group><article-title>Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications</article-title><source>Gut</source><volume>70</volume><issue>1</issue><year>2021</year><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">32350089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2020-320726</pub-id><pub-id pub-id-type="pmcid">PMC7211065</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Uson</surname><given-names>P.L.S.</given-names></name><name name-style="western"><surname>Samadder</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Riegert-Johnson</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study</article-title><source>Clin Transl Gastroenterol</source><volume>12</volume><issue>10</issue><year>2021</year><object-id pub-id-type="publisher-id">e00414</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ctg.0000000000000414</pub-id><pub-id pub-id-type="pmcid">PMC8500569</pub-id><pub-id pub-id-type="pmid">34620795</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Mohindroo</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Jesus-Acosta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yurgelun</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mork</surname><given-names>M.</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>F.</given-names></name></person-group><article-title>The evolving paradigm of germline testing in pancreatic ductal adenocarcinoma and implications for clinical practice</article-title><source>Surg Pathol Clin</source><volume>15</volume><issue>3</issue><year>2022</year><fpage>491</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">36049831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.path.2022.05.004</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Krepline</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Geurts</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>George</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer</article-title><source>Surgery</source><volume>169</volume><issue>3</issue><year>2021</year><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">32826069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.surg.2020.06.038</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Mahadevan</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Universal Lynch syndrome screening should be performed in all upper tract urothelial carcinomas</article-title><source>Am J Surg Pathol</source><volume>42</volume><issue>11</issue><year>2018</year><fpage>1549</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">30148743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000001141</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bujanda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cuatrecasas</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Identification of Lynch syndrome carriers among patients with small bowel adenocarcinoma</article-title><source>Cancers (Basel)</source><volume>13</volume><issue>24</issue><year>2021</year><fpage>6378</fpage><pub-id pub-id-type="pmid">34944998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13246378</pub-id><pub-id pub-id-type="pmcid">PMC8699558</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Marabelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair&#8211;deficient cancer: results from the phase II KEYNOTE-158 study</article-title><source>J Clin Oncol</source><volume>38</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">31682550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.19.02105</pub-id><pub-id pub-id-type="pmcid">PMC8184060</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sekine</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis</article-title><source>Gastric Cancer</source><volume>24</volume><issue>2</issue><year>2021</year><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">32794040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10120-020-01113-0</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Ajani</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>D'Amico</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Bentrem</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology</article-title><source>J Natl Compr Cancer Netw</source><volume>23</volume><issue>5</issue><year>2025</year><fpage>169</fpage><lpage>191</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2025.0022</pub-id><pub-id pub-id-type="pmid">40341199</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Banno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yanokura</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Features of ovarian cancer in Lynch syndrome (Review)</article-title><source>Mol Clin Oncol</source><volume>2</volume><issue>6</issue><year>2014</year><fpage>909</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">25279173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mco.2014.397</pub-id><pub-id pub-id-type="pmcid">PMC4179837</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Cost-effectiveness analysis of tumor testing for BRCA pathogenic variants in epithelial ovarian cancer</article-title><source>Am J Clin Oncol</source><volume>48</volume><issue>7</issue><year>2025</year><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">40138181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/COC.0000000000001187</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Fujii</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mochizuki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dreike</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeter</surname><given-names>J.M.</given-names></name></person-group><article-title>Genetic drivers in sebaceous neoplasms: a review of germline and somatic mutations and their role in treatment and management strategies</article-title><source>Cancers (Basel)</source><volume>17</volume><issue>4</issue><year>2025</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers17040659</pub-id><pub-id pub-id-type="pmcid">PMC11852771</pub-id><pub-id pub-id-type="pmid">40002254</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Kunnackal John</surname><given-names>G.</given-names></name><name name-style="western"><surname>Das Villgran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Caufield-Noll</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giardiello</surname><given-names>F.M.</given-names></name></person-group><article-title>Comparison of universal screening in major lynch-associated tumors: a systematic review of literature</article-title><source>Fam Cancer</source><volume>21</volume><issue>1</issue><year>2022</year><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">33426601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10689-020-00226-w</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>M&#248;ller</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sepp&#228;l&#228;</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Cancer risk and survival in <italic toggle="yes">path_MMR</italic> carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database</article-title><source>Gut</source><volume>67</volume><issue>7</issue><year>2018</year><fpage>1306</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">28754778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2017-314057</pub-id><pub-id pub-id-type="pmcid">PMC6031262</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0195">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary Material</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0190">We are grateful to all the patients and participants for their time and involvement in the study.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0200">Supplementary data related to this article can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.eclinm.2025.103618" id="intref0015">https://doi.org/10.1016/j.eclinm.2025.103618</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>